View:

Download DOC

Download PDF

Download XLS

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

Table of Contents

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                                                   EXHIBIT 10.24

                    JOINT COLLABORATION AND LICENSE AGREEMENT

         THIS JOINT COLLABORATION AND LICENSE AGREEMENT (the "Agreement") is
made effective as of the 16th day of March, 2004 (the "Effective Date") by and
between GTx, Inc., a Delaware corporation having its principal place of business
at 3 North Dunlap St., 3rd Floor, Memphis, Tennessee 38163 ("GTx") and Ortho
Biotech Products L.P., a limited partnership having its principal place of
business at Route 22 East, Bridgewater, NJ 08807 ("Ortho"), each on behalf of
itself and its Affiliates. GTx and Ortho are sometimes referred to herein
individually as a "Party" and collectively as the "Parties", and references to
"GTx" and "Ortho" shall include their respective Affiliates.

                                    RECITALS

         Ortho is a wholly owned subsidiary of Johnson & Johnson, a
multinational healthcare company with research, development and marketing
activities worldwide, which desires to obtain additional potential drug products
for osteoporosis and wasting, and possible other indications.

         GTx is a men's healthcare company, which is developing compounds,
including Andarine, an orally active, non-steroidal, selective androgen receptor
modulator (SARM). GTx has conducted several Phase I clinical trials of Andarine
and is planning Phase II and III clinical trials of such compound.

         The Parties desire to develop and commercialize Andarine and possibly
other specified SARM compounds throughout the world.

                                   ARTICLE I

                                   DEFINITIONS

         The following terms shall have the following meanings as used in this
Agreement:

         1.1 "Active Ingredient" means the material(s) in the Collaboration
Product which provide its pharmacological activity.


         1.2 "Additional Collaboration Compound" means any Collaboration
Compound selected for Development other than, and in addition to, Andarine or a
Replacement Collaboration Compound for Andarine.

         1.3 "Affiliate" means an entity that, directly or indirectly, through
one or more intermediaries, controls, is controlled by or is under common
control with GTx or Ortho. For the purposes of this definition, the term
"control" (including, with correlative



meanings, the terms "controlled by" and "under common control with") as used
with respect to a Party, shall mean the possession, directly or indirectly, of
the power to direct, or cause the direction of, the management or policies of
such person or entity, whether through the ownership of voting securities, by
contract or otherwise.

         1.4 "Andarine" means [ * ], and [ * ] that have the activity described
in Section 1.36(2).


         1.5 "Business Day" means a day on which banking institutions in New
York, NY are open for business.


         1.6 "Clinical Studies" means human studies designed to measure the
Safety, efficacy, Tolerability and appropriate dosage of a Collaboration
Compound and/or Collaboration Product. Clinical Studies includes Phase I
Clinical Trial, Phase IIA Clinical Trial, Phase IIB Clinical Trial, Phase III
Clinical Trial, Phase IIIB Clinical Trial, and Phase IV Clinical Trial, as
defined herein.

         1.7 "Collaboration Compound" means (i) initially, Andarine and (ii) any
other GTx SARM Compound selected by Ortho for Development pursuant to this
Agreement. Collaboration Compounds include without limitation Additional
Collaboration Compounds and Replacement Collaboration Compounds.

         1.8 "Collaboration Product" means a drug product for use in humans in a
form suitable for sale to an end user and/or for use in conducting Clinical
Studies, containing as an Active Ingredient at least one Collaboration Compound.

         1.9 "Combination Product" means (i) any pharmaceutical product that
consists of a Collaboration Product that also contains another Active Ingredient
that is not a Collaboration Compound, or (ii) any combination of a Collaboration
Product and another pharmaceutical product that is not a Collaboration Product
where such products are not formulated together but are sold together for a
single invoiced price.

         1.10 "Commercialization Activities" means activities relating to the
manufacture of a Collaboration Product for sale to end users, or to the
marketing and sale of a Collaboration Product, including Pre-Marketing
activities, which in the Co-Promotion Territory is undertaken pursuant to a
Marketing and Sales Plan.

         1.11 "Confidential Information" shall have the meaning set forth in
Section 9.1.


         1.12 "Control" or "Controlled" means the possession of the right to
grant a license or sublicense to intangible property rights (including patent
rights, know-how and/or trade secret information), and the right to provide
access to or cross-reference to regulatory filings or other data or information,
in each case to the extent not in violation of the terms of any pre-existing
agreement or other arrangement with any Third Party. "Control" expressly
includes the right of ownership, in whole or in part, unless the Party having
such right is restricted by contract or under law from granting such a license,
access or right to reference.

                                       2



         1.13 "Co-Promotion" shall have the meaning set forth in Article VI, and
"Co-Promote" shall have a correlative meaning.

         1.14 "Co-Promotion Territory" means the United States, but only after
GTx exercises its option to Co-Promote a Collaboration Product to the GTx
Audience, on a Collaboration Product by Collaboration Product basis.

         1.15 "Detail" (or "Details" and "Detailing") means, with respect to the
Collaboration Product, the activity undertaken by a sales representative [ * ]
to provide [ * ] of the Collaboration Product, in a fair and balanced manner
consistent with the requirements of the Food Drug and Cosmetics Act, including
but not limited to, the regulations of 21 C.F.R. 202, and [ * ] in an effort to
increase the number of physicians prescribing the Collaboration Product and/or
the number of prescriptions for Collaboration Product, but excluding [ * ].

         1.16 "Development" or "Develop" means activities relating to obtaining
Regulatory Approval of Collaboration Products, and activities relating to
developing and scaling up the ability to manufacture and to continue to
manufacture Collaboration Compounds and Collaboration Products, including
activities of Third Party manufacturers to develop such manufacturing
capabilities for Collaboration Products. Development includes but is not limited
to Pre-Clinical Studies, pharmacology studies, toxicology studies, formulation,
manufacturing process development and scale-up (including bulk compound
production), quality assurance and quality control, technical support,
pharmacokinetic studies, Clinical Studies, regulatory affairs activities and
outside counsel regulatory legal services. For clarity, Development shall not
include medicinal chemistry efforts directed at the production of new chemical
variants of any GTx SARM Compound that are not themselves GTx SARM Compounds,
but may include (to the extent provided in the Development Plan) the production
of modified GTx SARM Compounds that contain radioactive isotopes (whether or not
such modified compounds are included in GTx SARM Compounds) or other labeling or
tracing residues that are used in analyzing the activity, pharmacokinetics or
pharmacodynamics of Collaboration Compounds as provided in the Development Plan,
and activities directed toward developing a process for manufacturing
Collaboration Compounds.

         1.17 "Development Budget" shall have the meaning set forth in Article
IV.

         1.18 "Development Expenses" means the expenses incurred by a Party or
for its account by a Third Party (including capital expenditures made by a Third
Party and reimbursed by a Party) which are generally consistent with a
Development Plan and Development Budget and are specifically attributable to the
Development of a Collaboration Compound or Collaboration Product not otherwise
recovered or reimbursed. Development Expenses shall include, but are not limited
to, the cost of labor (calculated, as to GTx, as provided in Section 4.5) and
materials incurred in connection with Pre-Clinical and Clinical Studies (whether
conducted internally or by a Third Party, individual investigators or
consultants), toxicological, pharmacological, pharmacokinetic, metabolic,
analytical, formulation, and chemical studies, final product scale-up, and
qualification and validation batches as required by the FDA for the purpose of
obtaining

                                       3



Regulatory Approval of a Collaboration Product, and costs (and related fees) for
preparing, submitting, reviewing or developing data or information for the
purpose of submission to a governmental authority to obtain and/or maintain
Regulatory Approval of a Collaboration Product.

         1.19 "Development Plan" shall have the meaning set forth in Article IV.

         1.20 "Drug Approval Application" means an application for Regulatory
Approval required before commercial sale or use of a Product as a drug in a
regulatory jurisdiction.

         1.21 "Education" means professional and customer education, through any
means, including (i) articles appearing in journals, newspapers, magazines, or
other media, including direct mail and electronic media; (ii) seminars, exhibits
and conventions; (iii) educational literature, visual aids, three dimensional
educational items, and other educational materials; (iv) market research; and
(v) symposia, advisory boards and opinion leader development activities;
provided, however, that such term shall exclude direct sales force activity. All
such Education means must be within current healthcare compliance guidelines.

         1.22 "Effective Date" shall have the meaning set forth on page one of
this Agreement.

         1.23 "EMEA" means the European Medicine Evaluation Agency or any
successor thereto.

         1.24 "Executive Officers" means the Chief Executive Officer of GTx (or
a senior officer of GTx designated by GTx's Chief Executive Officer) and the
President of Ortho (or a senior officer of Ortho or one of its Affiliates).

         1.25 "FDA" means the United States Food and Drug Administration or any
successor thereto.

         1.26 "First Collaboration Compound" means Andarine or its Replacement
Collaboration Compound.

         1.27 "[ * ]" means [ * ].

         1.28 "FTE" means the equivalent of the work of one (1) employee full
time for one (1) calendar year (consisting of at least a total of [ * ] per
calendar year) of work pursuant to the Development Plan with respect to
Collaboration Products. Any employee who devotes less than [ * ] per calendar
year shall be treated as an FTE on a pro-rata basis calculated by dividing the
actual number of hours worked during such calendar year by [ * ].

         1.29 "FTE Cost" means the cost to GTx of its [ * ] personnel directly
dedicated to the execution of the Development Plan [ * ], and shall be
calculated by multiplying the

                                       4



FTE Rate by the number of GTx employees, agents or independent contractors
performing such Development pursuant to the Development Plan.

         1.30 "FTE Rate" means, as of the Effective Date, [ * ] per FTE. Such
rate shall be adjusted annually to reflect the total percentage increase in the
U.S. Consumer Price Index for the time period from the Effective Date until the
time at which such index was recalculated at the time of adjustment (with the
first adjustment to occur January 1, 2005, with subsequent adjustments on each
anniversary thereof).

         1.31 "Generic" means a product that contains the same chemical entity
as a Collaboration Product and that has received regulatory approval to be
marketed and sold for an Indication for which the Collaboration Product is
marketed and sold. In the United States, Generics shall only include those
products approved under an ANDA based on the NDA of the Collaboration Product.

         1.32 "GTx Audience" means those urologists who are licensed to practice
in the United States to whom GTx will promote Collaboration Product, as
designated pursuant to Section 6.3.

         1.33 "GTx Know-how" means Information which (i) GTx discloses to Ortho
under this Agreement and (ii) is within the Control of GTx. Notwithstanding
anything herein to the contrary, GTx Know-how shall exclude GTx Patents.

         1.34 "GTx/Ortho Development" means Development of Collaboration
Compounds for Indications that are primarily directed to the treatment of male
health diseases and/or conditions.

         1.35 "GTx Patent" means the rights granted by any governmental
authority under a Patent which claims Andarine and/or GTx SARM Compounds, or
methods of using and processes for making such compounds, which Patent is owned
or Controlled by GTx. A list of the GTx Patents identified as of the Effective
Date is attached hereto as Exhibit A. GTx Patents include without limitation
GTx's interest in any Joint Patents.

         1.36 "GTx SARM Compounds" means Andarine and/or non-steroidal selective
androgen receptor modulators that (1) [ * ], are [ * ], any [ * ] issued, any [
* ] and [ * ]; and (2) (a) [ * ]; (b) [ * ]; and (c)(i) [ * ]; or (ii) [ * ]; or
(iii) [ * ]. GTx SARM Compounds shall also include [ * ] described in (1) that
also [ * ] in (2). For avoidance of doubt, if a compound is described in (1) but
does not also meet the requirements of (2), such compound shall not be a GTx
SARM Compound and GTx shall retain all rights to such compound. It is understood
by the Parties that GTx has [ * ] and that [ * ] may include GTx SARM Compounds
and/or Excluded SARM Compounds. "Excluded SARM Compounds" means compounds that
are [ * ] and/or compounds that are included in Exhibit D2. For example, the GTx
Patents listed on Exhibit A includes continuation-in-part applications which
include Excluded SARM Compounds. GTx shall retain all rights to Excluded SARM
Compounds. For avoidance of doubt, the parties have set forth on Exhibit D1
certain compounds that, as of the Effective Date, are [ * ] and are included
within clause (1) of the first sentence of this Section 1.36 (and are therefore
eligible to be

                                       5



GTx SARM Compounds if they also fulfill the requirements of clause (2) of this
Section 1.36), and on Exhibit D2 certain compounds that are, as of the Effective
Date, Excluded SARM Compounds.

         1.37 "IND" shall mean (i) an Investigational New Drug Application as
defined in the United States Food, Drug and Cosmetic Act and applicable
regulations promulgated thereunder by the FDA, or (ii) the equivalent
application to the equivalent agency in any other country or group of countries,
the filing of which is necessary to commence clinical testing of a
pharmaceutical product in humans in a particular jurisdiction.

         1.38 "Indication" means any disease or condition for which a
Collaboration Compound may have therapeutic, ameliorative or preventive activity
and for which a Collaboration Compound can be Developed.

         1.39 "Information" means (i) techniques and data relating to
Collaboration Compounds, Collaboration Products, Combination Products or GTx
SARM Compounds to the extent provided to a Party for use in joint Development,
or for Commercialization thereof, including (but not limited to) inventions,
practices, methods, knowledge, know-how, skill, experience, test data including
pharmacological, toxicological, Pre-Clinical Studies and clinical test data,
analytical and quality control data, marketing, pricing, distribution, cost,
sales and manufacturing data or descriptions, and compounds, compositions of
matter, assays and biological materials related thereto.

         1.40 "Joint Development Committee" or "JDC" means the committee
established pursuant to Article II.

         1.41 "Joint Patent" shall have the meaning set forth in Section 10.4.

         1.42 "Koseisho" means the Japanese Ministry of Health and Welfare, or
any successor agency thereto.

         1.43 "Launch Date" means the date of the first offer for commercial
sale, following Regulatory Approval, of a Collaboration Product.

         1.44 "Major European Country" means any of the United Kingdom, France,
Germany, Spain and Italy.

         1.45 "Market Exclusivity" means, as to a given country, a given product
and a given time period, that no Generic version of such product is then being
sold in such country.

         1.46 "Marketing" means the sale, promotion and advertising of a
Collaboration Product in the Co-Promotion Territory as set forth in Article VI
and in the Marketing and Sales Plan.

         1.47 "Marketing Expenses" means the costs that are generally consistent
with a Marketing and Sales Plan that are incurred after the Launch Date of a
Collaboration

                                       6



Product and are specifically attributable to the sale, promotion, advertising,
and marketing of such Collaboration Product. Marketing Expenses shall include
costs of Phase IV Clinical Trials.

         1.48 "Marketing and Sales Committee" shall have the meaning set forth
in Section 6.4.

         1.49 "Marketing and Sales Plan" shall have the meaning set forth in
Section 6.5.

         1.50 "Material Breach" shall have the meaning set forth in Section
13.2(e).

         1.51 "NDA" means a complete New Drug Application and all amendments and
supplements thereto filed with the FDA, including all documents, data, and other
information concerning a Collaboration Product, which are necessary for, or
included in, an application for Regulatory Approval by the FDA to market such
Collaboration Product, as more fully defined in 21 C.F.R. Section 314.5 et seq.

         1.52 "NDA Approval" means the approval of an NDA by the FDA required
before commercial sale or use of a Collaboration Product as a drug in the United
States.

         1.53 "Net Sales" means, consistent with, in the United States,
generally accepted accounting principles and, in the rest of the Royalty Bearing
Territory, Ortho worldwide practices and procedures, and in each such case as
consistently applied across the Ortho pharmaceutical product line, the amount
invoiced by Ortho, its Affiliates, and its distributors and sub-licensees to
Customers for sales of licensed Product in the Royalty Bearing Territory, less
accruals estimated, credits taken, and actual payments (to the extent not
previously accrued) made for:

                  (a) discounts, credits, retroactive price reductions, rebates,
refunds, charge backs, allowances and adjustments granted to non-sublicensee
Third Parties, including Medicaid, and managed care and similar types of
rebates, rejections, market withdrawals, recalls (provided such recalls are in
accordance with Section 6.22 of this Agreement) and returns, and administrative
fees charged by hospital buying groups and managed care organizations in the
United States, each to the extent consistent with Ortho's usual course of
dealing for its products other than the Products;

                  (b) trade, quantity and cash discounts and rebates actually
allowed or given (other than to a distributor that is an Affiliate of Ortho),
each to the extent consistent with Ortho's usual course of dealing for its
products other than the Product;

                  (c) sales, excise, turnover, value-added, and similar taxes
assessed on the sale of the Product (other than income taxes of Ortho, its
Affiliates or sublicensees), and import and customs duties;

                  (d) shipping and insurance charges, postage, and freight out;
and

                  (e) government imposed rebates or discounts.

                                       7



Sales of Product by and between Ortho and its Affiliates and sublicensees are
not sales to Third Parties and shall be excluded from Net Sales calculations for
all purposes. Sales of Product for use in conducting clinical trials of Product
in a country in order to obtain the first Regulatory Approval of Product in such
country shall be excluded from Net Sales calculations for all purposes. Net
Sales shall be determined in a manner consistent for all products sold by or on
behalf of Ortho and in accordance with applicable U.S. generally accepted
accounting principles.

In the event the Product is sold as part of a Combination Product in a country,
the Net Sales of the Product, for the purposes of determining payments based on
Net Sales, shall be determined by multiplying the Net Sales of the Combination
Product in such country, during the applicable Net Sales reporting period, by
the fraction, A/(A+B), where:

A is the average sale price of the Product by Ortho, its Affiliates or
sublicensees when sold separately in finished form in such country and B is the
average sale price by Ortho, its Affiliates or sublicensees of the other
product(s) included in the Combination Product when sold separately in finished
form in such country, in each case during the applicable Net Sales reporting
period.

In the event the Product is sold as part of a Combination Product and is sold
separately in finished form in such country, but the other product(s) included
in the Combination Product are not sold separately in finished form in such
country, the Net Sales of the Product, for the purposes of determining payments
based on Net Sales, shall be determined by multiplying the Net Sales of the
Combination Product in such country by the fraction C/D where:

C is the average sale price, in such country, of the Product contained in such
Combination Product when sold separately and D is the average sale price, in
such country, for the Combination Product, in each case during the applicable
Net Sales reporting period. Under no circumstances can C/D exceed one hundred
percent (100%).

In the event that the Product is not sold separately in finished form in the
country, but all of the other product(s) included in the Combination Product in
such country are sold separately, the Net Sales of the Product, for the purposes
of determining payments based on Net Sales, shall be determined by multiplying
the Net Sales of the Combination Product in such country by the fraction
(D-E)/D, where:

D is the average sale price, in such country, of the Combination Product, and E
is the average sale price of the other product(s) included in the Combination
Product in finished form in such country, in each case during the applicable Net
Sales reporting period, provided that in no event shall (D-E)/D be [ * ].

In the event that the Net Sales of the Product when included in a Combination
Product cannot be determined using the methods above, Net Sales for the purposes
of determining payments based on Net Sales shall be calculated by multiplying
the Net Sales of the Combination Product by the fraction of F/(F+G) where:

                                       8



F is the fair market value of the Product and G is the fair market value of all
other pharmaceutical product(s) included in the Combination Product, as
reasonably determined in good faith by the Parties.

         1.54 "Ortho Development" means all Development other than the GTx/Ortho
Development.

         1.55 "Ortho Know-how" means Information which (i) Ortho discloses to
GTx under this Agreement and (ii) is within the Control of Ortho.
Notwithstanding anything herein to the contrary, Ortho Know-how shall exclude
Ortho Patents.

         1.56 "Ortho Patent" means the rights granted by any governmental
authority under a Patent which covers an invention relating to the composition
of matter, formulation, method of making or method of using Collaboration
Compounds or Collaboration Products, which Patent is Controlled by Ortho. As of
the Effective Date, Ortho has not identified any Ortho Patents. Ortho Patents
include Ortho's interest in any Joint Patents.

         1.57 "Osteoporosis Indication" means the treatment of [ * ].

         1.58 "[ * ]" means [ * ].

         1.59 "Patent" means (i) valid and enforceable United States or foreign
patents, reexaminations, reissues, renewals, extensions, term restorations, and
foreign counterparts thereof, and (ii) pending applications for United States or
foreign patents thereof.

         1.60 "Patent Expenses" means the fees, expenses and disbursements of
outside counsel, and payments to Third Party agents, incurred in connection with
the preparation, filing, prosecution and maintenance of GTx Patents or Ortho
Patents covering Collaboration Compounds or Collaboration Products, including
the costs of patent interference and opposition proceedings but excluding the
costs of any other Patent enforcement proceedings.

         1.61 "Phase I Clinical Trial" means that portion of the clinical
development program which provides for the first introduction into humans of a
Product with the purpose of determining human toxicity, metabolism, absorption,
elimination and other pharmacological action, as more fully defined in 21 C.F.R.
Section 312.21(a).

         1.62 "Phase IIA Clinical Trial" means that portion of the clinical
development program which provides for the initial trials of a Collaboration
Compound on a limited number of patients for the purpose of determining whether
the Collaboration Compound affects a surrogate marker or indicator of
pharmacological or clinical activity in the proposed therapeutic indication.

         1.63 "Phase IIB Clinical Trial" means that portion of the clinical
development program which provides for the definitive, well controlled clinical
trials of a Collaboration Compound in patients for the purpose of determining
the safe and effective

                                       9



dose range in the proposed therapeutic indication, as more fully described in 21
C.F.R. Section 312.21(b).

         1.64 "Phase III Clinical Trials" means that portion of the clinical
development program which provides for continued trials of a Product on
sufficient numbers of patients to establish the safety and efficacy of a Product
and generate pharmaco-economic data to support Regulatory Approval in the
proposed therapeutic indication, as more fully defined in 21 C.F.R. Section
312.21(c).

         1.65 "Phase IIIB Clinical Trials" means product support clinical trials
of a Collaboration Product, which is not required for receipt of initial
Regulatory Approval but which may be useful in providing additional drug profile
data or expansion of the Collaboration Product's label claim, and which is
commenced after NDA filing but before NDA Approval.

         1.66 "Phase IV Clinical Trials" means product support clinical trials,
including but not limited to trials including new drug delivery systems, of a
Collaboration Product with an approved label claim that is commenced after
receipt of Regulatory Approval in the country where such trial is being
conducted. These trials shall be considered a part of Commercialization.

         1.67 "Pre-Clinical Studies" means studies of a Collaboration Product in
animals other than humans, including those studies conducted in whole animals
and other test systems, designed to determine the toxicity, bioavailability, and
pharmacokinetics of a Collaboration Compound and whether the Collaboration
Compound has a desired effect.

         1.68 "Pre-Marketing" means Commercialization Activities undertaken
prior to and in preparation for the launch of a Collaboration Product,
consistent with a Marketing and Sales Plan and prior to the first commercial
launch of such Collaboration Product. Pre-Marketing activities shall include,
but are not limited to, advertising, Education, market research, Phase IIIB
Clinical Trials, Phase IV Clinical Trials, sales force training, trademark
activities (including selection, filing, prosecution and enforcement) and other
activities included within the Marketing and Sales Plan prior to the first
commercial launch of such Collaboration Product.

         1.69 "Products" means Collaboration Products.

         1.70 "Proof of Concept Trial" means any Phase IIA Clinical Trial or
Phase IIB Clinical Trial that is designed to demonstrate that a Collaboration
Product meets clinical criteria established by the JDC with respect to a given
indication.

         1.71 "Regulatory Agency" means any governmental authority, including
without limitation the FDA or EMEA, with responsibility for granting any
licenses or approvals or granting pricing and/or reimbursement approvals
necessary for the marketing and sale of a Collaboration Product in any country
or group of countries.

                                       10


         1.72 "Regulatory Approval" means any approvals by government pricing or
health authorities in a country or supra-national organization (including, but
not limited to, FDA and EMEA), product and/or establishment licenses,
registrations or authorizations of any federal, state or local regulatory
agency, department, bureau or other governmental entity, in each case that are
necessary for the commercial manufacture, use, storage, importation, export,
transport or sale of Collaboration Products in a regulatory jurisdiction.

         1.73 "Replacement Collaboration Compound" means a GTx SARM Compound
that is selected to replace a Collaboration Compound then under development as
described in Section 4.6.

         1.74 "Royalty Bearing Product" means a Collaboration Product marketed
directly or indirectly by Ortho, its Affiliate or sublicensee alone or together
with GTx or its Affiliates in the Royalty Bearing Territory.

         1.75 "Royalty Bearing Sales" means the Net Sales in the Royalty Bearing
Territory.

         1.76 "Royalty Bearing Territory" means the world.

         1.77 "Royalty Term" shall have the meaning set forth in Section 3.5.

         1.78 "Safety" means the absence of adverse experiences associated with
the administration of a drug to a patient that are significant, serious or life
threatening to the patient or demonstrate significant toxicological effect(s) of
such drug on one or more body tissues that are not balanced by a countervailing
benefit to the patient. The Safety of a product will be determined in view of
the risk to benefit relationship of such product in the relevant patient
population.

         1.79 "[ * ]" means [ * ].

         1.80 "Third Party" means any entity other than GTx or Ortho and their
respective Affiliates.

         1.81 "Tolerability" means the absence of adverse experiences, other
than those that are Safety-related experiences, associated with administration
of a drug to patients that such patients, or their physicians, deem unpleasant
to an extent that can materially and adversely affect market potential or market
penetration of a Collaboration Product.

         1.82 "Trademark Expenses" means the fees, expenses and disbursements of
outside counsel, and payments to Third Party agents incurred in connection with
the preparation, filing, prosecution, registration and maintenance of trademarks
covering Collaboration Compounds or Collaboration Products, including the costs
of trademark interference and opposition proceedings, but excluding other
trademark enforcement proceedings.

                                       11



         1.83 "Unit Net Sales Price" means the average Net Sales amount received
during either the applicable calendar quarter (as used in Section 7.1) or during
the applicable period (as used in Section 13.6) by Ortho, its Affiliates or
sublicensees for each tablet or other dosage form of a Collaboration Product
written by a Urologist and filled and sold by a pharmacist in the United States.

         1.84 "Urologist" means a urologist licensed to practice in the United
States, or a nurse practitioner or physician assistant who works for such a
urologist.

         1.85 "UTRF" means the University of Tennessee Research Foundation.

         1.86 "Valid Patent Claim" means a claim (a) of any issued, unexpired
patent that has not been revoked or held unenforceable or invalid by a decision
of a court or governmental agency of competent jurisdiction from which no appeal
can be taken, or with respect to which an appeal is not taken within the time
allowed for appeal, and that has not been disclaimed or admitted to be invalid
or unenforceable through reissue, disclaimer or otherwise, or (b) of any patent
application that has not been cancelled, withdrawn or abandoned or been pending
more than seven (7) years.

         1.87 "Wasting Indication" means the treatment of the effects of
diseases involving a reduction in lean body weight, whether due to [ * ] or
other chronic medical conditions.

                                   ARTICLE II

                                   MANAGEMENT

         2.1 Joint Development Committee.


                  (a) Formation of JDC. GTx and Ortho shall form a Joint
Development Committee ("JDC"). The JDC shall be comprised of equal numbers (up
to three (3) from each Party) of appropriately expert and experienced
individuals, with one such person assigned by each Party as such Party's
co-chair. Either Party may designate a substitute for a committee member to
participate in the event one of that Party's regular committee members is unable
to be present at a meeting.

                  (b) Meetings. Meetings of each of the JDC may be called by
either Party on ten (10) calendar days written notice to the other unless such
notice is waived by the Parties. Such committees may be convened, polled or
consulted from time to time by means of telecommunication, video communication,
or correspondence. The JDC will meet at least quarterly, at sites to be
designated by the chairpersons of such committees or through teleconference or
video conference, as agreed upon by the JDC.

                  (c) Agendas. Each Party will disclose to the other proposed
agenda items along with appropriate Information at least five (5) calendar days
in advance of each meeting of the JDC.

                                       12



                  (d) Responsibilities of the JDC. The JDC will oversee the
Parties' efforts for Ortho Development and will oversee and coordinate the
Parties' efforts with respect to GTx/Ortho Development. The JDC will review and
comment on the Development Plans and Development Budgets and make
recommendations with respect to adjustment of GTx/Ortho Development, budget and
timetables and the assessment of whether a Collaboration Compound shall proceed
to the next stage of Development. Ortho will update the JDC periodically, but at
least quarterly, of all Development activities. The JDC will review and approve,
with respect to GTx/Ortho Development, the addition of new indications, the
ceasing of Development of Andarine, and the addition of a Replacement
Collaboration Compound or an Additional Compound. In, addition, the JDC shall
review and approve any proposal by GTx to designate a compound not to be a GTx
SARM Compound, as defined herein. In this regard, GTx agrees to provide the JDC
with sufficient information and data in connection with [ * ] so that the JDC
can agree or disagree with GTx's position. Such information shall be provided at
a JDC meeting and the JDC shall have thirty (30) calendar days after it receives
the information and data to decide whether or not it agrees with GTx. If the JDC
disagrees with GTx's position, GTx may proceed to develop and commercialize its
compound independent of this collaboration, provided, however, Ortho shall
retain its rights to arbitrate the classification of such compound under Article
XV (and GTx may also initiate such an arbitration in order to clarify its rights
to such compound). If the JDC agrees that the compound is not a GTx SARM
Compound, Ortho shall promptly provide to GTx a written statement confirming
that Ortho has no rights under this Agreement in or to such compound.

                  (e) Decisions by the JDC.

                           (i) Ortho shall present to the JDC the portion of the
Development Plan and Development Budget that relates to the Ortho Development at
the same level of detail as is contained in the portion of the Development Plan
and Development Budget that relates to the GTx/Ortho Development. However, this
presentation and any subsequent discussion of the contents of the portion of the
Development Plan and Development Budget related to the Ortho Development shall
be for advisory purposes only.

                           (ii) All decisions by the JDC that relate to
GTx/Ortho Development shall be made unanimously, after an open and informed
discussion of the matters as to which decisions are being made, including, but
not limited to those matters relating to the portion of the Development Plan and
Budget directed to GTx/Ortho Development. If the JDC is unable to make a
unanimous decision on such matters, the matter will be referred to the Executive
Officers of GTx and Ortho. If such officers do not reach agreement on such
matter within twenty (20) calendar days after it is referred to them, then
subject to Section 4.1, the decision of Ortho on such matter will be final and
determinative, so long as such decision does not contradict or modify the terms
of this Agreement.

                                       13



                  (f) Subcommittees of the JDC. The JDC will have the power to
form subcommittees with equal (unless otherwise agreed in writing) and
appropriate representation from GTx and Ortho.

                                  ARTICLE III

            LICENSING FEES; MILESTONE PAYMENTS; ROYALTIES; REPORTING

         3.1 Licensing Fee.

                  (a) As partial payment for the licenses granted by GTx
pursuant to this Agreement, Ortho shall pay to GTx a non-refundable,
non-creditable $6.0 Million license fee within fifteen (15) Business Days after
the Effective Date of this Agreement. Payment shall be made by wire transfer.

                  (b) As a partial payment for the licenses granted by GTx
pursuant to this Agreement, Ortho shall pay to GTx a non-refundable,
non-creditable [ * ] at the time that [ * ] of a Collaboration Product for [ *
]. Ortho will pay such amount within fifteen (15) Business Days after receipt of
an invoice from GTx. Payment shall be made by wire transfer.

         3.2 Milestone Payments. In addition to the payments due to GTx under
Section 3.1, Ortho shall make the following non-refundable, non-creditable
milestone payments to GTx after the first occurrence of each milestone that
follows, unless, at anytime prior to the date on which such milestone payment is
due, Ortho has provided notice of termination, which termination thereafter
becomes effective. The payments set forth herein shall each be due and payable
by Ortho within [ * ] Business Days following receipt from GTx of a notice and
invoice regarding the achievement of the milestone event set forth herein.
Payment shall be made by wire transfer.

                  (a) First Collaboration Compound:



                         MILESTONE EVENT                                  PAYMENT
                         ---------------                                  -------
                                                                       
[ * ] in a Proof of Concept Trial of a Collaboration Product for
the [ * ].**                                                              $[ * ]

[ * ] in a Proof of Concept Trial of a Collaboration Product for
the [ * ].**                                                              $[ * ]

[ * ] in a Phase III Clinical Trial of a Collaboration Product [
* ] for the [ * ].                                                        $[ * ]

[ * ] in a Phase III Clinical Trial of a Collaboration Product [
* ] for the [ * ].                                                        $[ * ]

Regulatory Approval by the FDA of a Collaboration Product [ * ]
for the [ * ].                                                            $[ * ]


                                       14






                         MILESTONE EVENT                                  PAYMENT
                         ---------------                                  -------
                                                                       
Regulatory Approval by the FDA of a Collaboration Product [ * ]
for the [ * ].                                                            $[ * ]

Regulatory Approval by the EMEA of a Collaboration Product [ * ]
for the [ * ].*                                                           $[ * ]

Regulatory Approval by the EMEA of a Collaboration Product [ * ]
for the [ * ].*                                                           $[ * ]

Regulatory Approval by the Koseisho of a Collaboration Product
[ * ] for the [ * ].                                                      $[ * ]

Regulatory Approval by the Koseisho of a Collaboration Product
[ * ] for the [ * ].                                                      $[ * ]


*If a centralized filing with the EMEA is not made for the relevant
Collaboration Product for the [ * ], but the JDC decides to pursue Regulatory
Approval in Europe using the mutual recognition procedure or on an individual
country basis, then the milestone shall be deemed to be achieved upon the Launch
Date for such Collaboration Product in the first Major European Country.

** This trial is [ * ] as proposed in [ * ], as applicable, is the [ * ].

For clarity, if a Collaboration Product is developed initially for [ * ], such [
* ] shall be the [ * ]. If such development is successful and such product is
commercialized for such [ * ], and Ortho develops such Collaboration Product for
[ * ], such [ * ] shall be a [ * ]. If development of such Collaboration Product
for such [ * ] is terminated, but such product is then developed and
commercialized for a [ * ], then for the purpose of calculating milestones
hereunder, any milestones that are due with respect to a [ * ] that were not
previously paid by Ortho for the Collaboration Product for a [ * ] shall be due
when such milestone is achieved for the [ * ] (i.e., the [ * ] would function as
a [ * ] for the purposes of this Section 3.2).

                  (b) Additional Collaboration Compounds:



                         MILESTONE EVENT                                 PAYMENT
                         ---------------                                 -------
                                                                      
[ * ] in a Proof of Concept Trial of a Collaboration Product [ * ].      $[ * ]

[ * ] in a Phase III Clinical Trial of a Collaboration Product [ * ].    $[ * ]


                                       15





                         MILESTONE EVENT                                 PAYMENT
                         ---------------                                 -------
                                                                      
Regulatory Approval by the FDA of a Collaboration Product [ * ].         $[ * ]

Regulatory Approval by the EMEA of a Collaboration Product [ * ].*       $[ * ]

Regulatory Approval by the Koseisho of a Collaboration Product [ * ].    $[ * ]



*If a centralized filing with the EMEA is not made for the relevant
Collaboration Product for the [ * ], but the JDC decides to pursue Regulatory
Approval in Europe using the mutual recognition procedure or on an individual
country basis, then the milestone shall be deemed to be achieved upon the Launch
Date for such Collaboration Product in the first Major European Country.

                  (c) Replacement Collaboration Compound. If the JDC (or Ortho,
with respect to Ortho Development) decides to cease Development of Andarine or
another Collaboration Compound that the Parties Develop in addition to Andarine
and decides to Develop, instead of the Collaboration Compound for which
Development was so terminated, another Collaboration Compound (a "Replacement
Collaboration Compound"), Ortho shall not be obligated to make the same
milestone payments for the Replacement Collaboration Compound as it already made
in connection with the Collaboration Compound which was replaced, and shall only
be obligated to make any milestone payments for the Replacement Collaboration
Compound that were not made for the Collaboration Compound that was replaced by
such Replacement Collaboration Compound. It is understood that in no event shall
Ortho be obligated to make the payment due pursuant to this Section 3.2 on any
milestone more than once with respect to the same Collaboration Compound (or its
"Replacement Collaboration Compound") regardless of the number of different
forms or formulations of the Collaboration Compound that are developed[ * ].

         3.3 Limitation on Milestone Payments. Other than the milestone payments
recited in Section 3.2, Ortho shall not be obligated to make any other milestone
payments in connection with Andarine, a Replacement Collaboration Compound, or
any Additional Collaboration Compound.

         3.4 Royalty Rates. Ortho shall pay to GTx an incremental, tiered
royalty equal to the applicable royalty rate set forth below multiplied by the
relevant portion of annual Royalty Bearing Sales of each Collaboration Product
sold in the Royalty Bearing Territory as follows:

                                       16





Portion of Annual Net Sales of Each Collaboration Product                   Rate
- ---------------------------------------------------------                   ----
                                                                        
First $[ * ]                                                               [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ] and < or = $[ * ]                                                 [ * ]

> $[ * ]                                                                   [ * ]



Said royalty shall be calculated as follows: Assume [ * ] of Net Sales of a
Collaboration Product in a calendar year, the royalty would be [ * ] = a royalty
of [ * ].

         3.5 Payment of Royalties. Within twenty (20) Business Days after the
end of each calendar quarter for which royalty fees are payable by Ortho to GTx
with respect to Net Sales in the Royalty Bearing Territory pursuant to Section
3.4, Ortho shall submit to GTx a report, on a country by country basis,
providing in reasonable detail an accounting of all Net Sales (including an
accounting of all unit sales of Product) made during such calendar quarter and
the calculation of such applicable royalty fees under Section 3.4. Within twenty
(20) Business Days after submission of such report, Ortho shall pay GTx all
royalties payable by it under Section 3.4 as indicated in the report by wire
transfer. Ortho will pay GTx royalties on Net Sales of each Collaboration
Product invoiced by Ortho, its Affiliates and its sublicensees at the rates
shown in Section 3.4 above.

                  (a) Royalties shall be payable on a product by product and
country by country basis until the later of (i) the expiration of the last to
expire Valid Claim of a GTx Patent or a Joint Patent claiming the composition of
matter for such Collaboration Product in such country (either, a "Relevant Valid
Claim"), or (ii) ten (10) years following the Launch Date of such Collaboration
Product in such country (such period of time, the "Royalty Term") where there
are no patents.

                  (b) Royalties shall be paid at the rate set forth in Section
3.4 during the Royalty Term, except in a given country where (A) no Relevant
Valid Claim covering the composition of matter of such Collaboration Product
exists during a calendar quarter for which royalties are being calculated under
Section 3.4, and (B) Market Exclusivity does not exist for such Collaboration
Product in such country [ * ] immediately prior to the [ * ]. If the conditions
of (A) and (B) are satisfied, then the royalty rates set forth in Section 3.4
shall be reduced for sales occurring during such calendar quarter by:

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of the number of all units of products
                  (including Collaboration Products) containing the Active
                  Ingredient contained in such Collaboration Product (such
                  number, "All Units") that are sold in such country;

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of All Units that are sold in such country;

                                       17



                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of All Units that are sold in such country;
                  or

                  [ * ], if the number of units of Collaboration Products
                  invoiced by Ortho, its Affiliates or sublicensees in such
                  country are [ * ] of All Units that are sold in such country.

         Market Exclusivity shall be deemed to exist during the [ * ] following
the Launch Date in each country.

         3.6 Payment of Third Party Royalties.

                  (a) In addition to the royalties of Section 3.4, [ * ] shall [
* ] any royalties due by GTx to UTRF under the Amended and Restated License
Agreement between GTx and UTRF dated June 3, 2002, and the Amended and Restated
License Agreement between GTx and UTRF dated June 14, 2002 (collectively, the
"UTRF Agreements"), with respect to the sale of Collaboration Products by Ortho,
its Affiliates or sublicensees. [ * ] shall make such payments [ * ].
Specifically, [ * ] shall deliver to UTRF true and accurate reports as required
under Section 5.2 of the UTRF Agreements, and shall pay all royalties due to
UTRF under Section 4.2 of the UTRF Agreements within the time periods required
therein. [ * ] shall provide copies of each such report to [ * ] simultaneously
with its delivery of such report to UTRF. In no event shall any amounts paid by
[ * ] hereunder be included as [ * ].

                  (b) If a Royalty Bearing Product is being sold in any country
with respect to which a Third Party owns or Controls a patent, from which GTx
has not obtained a license, and such Third Party is entitled to receive
royalties pursuant to a patent license required in order to make or sell the
composition of matter of the Collaboration Compound included in such Royalty
Bearing Product, then Ortho shall be entitled to [ * ] of any royalty paid to
such Third Party against amounts due to GTx pursuant to Sections 3.4 and 3.5,
provided, however, that in no event shall the royalty due to GTx pursuant to
Sections 3.4 and 3.5 be reduced by means of such offset to [ * ] of the royalty
otherwise payable thereunder.

         3.7 Ortho's Rights Upon Expiration of Royalty Term. Upon expiration of
the royalty term for a Royalty Bearing Product in a country as described above,
Ortho shall thereafter have a paid-up, non-exclusive license under the GTx
Know-How to make, have made, use, sell, offer for sale, have sold and import
that Royalty Bearing Product in that country.

         3.8 Compulsory License. If at any time and from time to time a Third
Party in any country shall, under the right of a compulsory license granted or
ordered to be granted by a competent governmental authority, manufacture, use or
sell any Collaboration Product, with respect to which royalties would be payable
to GTx pursuant to this Article, then Ortho may reduce the royalty on sales in
such country of such Collaboration Product, to [ * ].

                                       18



         3.9 Sales by Sublicensees. In the event Ortho, subject to the
provisions of this Agreement, grants licenses or sublicenses to others to make
or sell Royalty Bearing Products, such licenses or sublicenses shall include an
obligation for the licensee or the sublicensee to account for and report its
Royalty Bearing Sales of such Royalty Bearing Products on the same basis as if
such sales were Royalty Bearing Sales by Ortho, and Ortho shall pay royalties to
GTx as if the Royalty Bearing Sales of Ortho.

         3.10 Tax Matters.

                  (a) Ortho Payments to GTx Without Withholding. Ortho will make
all payments to GTx under this Agreement without deduction or withholding for
Taxes except to the extent that any such deduction or withholding is required by
law in effect at the time of payment; provided that Ortho shall use commercially
reasonable efforts to minimize any such required deductions or withholdings to
the extent permitted by applicable laws, rules and regulations.

                  (b) Ortho Payment of Tax. Any Tax required to be withheld on
amounts payable under this Agreement will promptly be paid by Ortho on behalf of
GTx to the appropriate governmental authority, and Ortho will furnish GTx with
proof of payment of such Tax. Any such Tax required to be withheld will be an
expense of and borne by GTx. Ortho will give notice of its intention to begin
withholding any such Tax in advance and cooperate to use reasonable and legal
efforts to reduce such Tax on payments made to GTx hereunder.

                  (c) Cooperation Between Ortho and GTx. Ortho and GTx will
cooperate with respect to all documentation required by any government taxing
authority or reasonably requested by Ortho to secure a reduction in the rate of
applicable withholding Taxes.

                  (d) GTx Indemnification for Ortho's Failure to Withhold. If
Ortho had a duty to withhold Taxes in connection with any payment it made to GTx
under this Agreement but Ortho failed to withhold, and such Taxes were assessed
against and paid by Ortho, then GTx will indemnify and hold harmless Ortho from
and against such Taxes. Notwithstanding anything to the contrary in this
Section, GTx shall not be responsible for indemnifying Ortho for interest and
penalties attributable to any period [ * ] written notice of such assessment or
proposed assessment to Ortho and ending on the date Ortho provides GTx written
notice of such assessment or proposed assessment, and provided further that GTx
shall be entitled to protest the assessment of such Tax. If Ortho makes a claim
under this Section 3.10(d), it will comply with the obligations imposed by
Section 3.10(b) as if Ortho had withheld Taxes from a payment to GTx.

                  (e) Tax. Solely for purposes of this Section, "Tax" or "Taxes"
means any present or future taxes, levies, imposts, duties, charges, assessments
or fees of any nature (including interest, penalties and additions thereto) that
are imposed by a government taxing authority on GTx's receipt of payments
hereunder. Notwithstanding the foregoing, "Tax" or "Taxes" shall not include
charges, value-added taxes, taxes

                                       19



imposed on Ortho's income, or assessments or fees of any nature (or any
interest, penalties or additions thereto) imposed by the FDA or any related or
successor agency.

                  (f) Protest. Ortho shall promptly notify GTx in writing of any
assessment, proposed assessment or other claim for any additional amount of Tax
assessed by the United States. Notwithstanding any other provision of this
Section, GTx may, at its own expense, protest any assessment, proposed
assessment, or other claim by any governmental authority for any additional
amount of Tax or seek a refund of such amounts paid if permitted to do so by law
or if the payment of such amounts are its ultimate contractual responsibility
under the terms of this Agreement. Ortho shall cooperate with GTx in any protest
by providing records, giving testimony and providing such additional information
or assistance as may reasonably be necessary to pursue such protest.

         3.11 United States Dollars. All dollar ($) amounts specified in this
Agreement are United States dollar amounts.

         3.12 Payments to or Reports by Affiliates. Any payment required under
any provision of this Agreement to be made to either Party, or any report
required to be made by any Party, shall be made to or by an Affiliate of that
Party if such Affiliate is designated by that Party as the appropriate recipient
or reporting entity.

         3.13 Payment of Additional Royalties. GTx shall receive an additional
royalty on sales of Collaboration Products that it Co-Promotes, as set forth in
Sections 7.1 and, if applicable, 13.6.

         3.14 Payments by Wire Transfer. Any payments due to GTx hereunder shall
be made by wire transfer to the following (or as provided in any alternative
instructions that GTx may provide by written notice to Ortho from time to time):
[ * ].

                                   ARTICLE IV

                                   DEVELOPMENT

         4.1 Development Responsibility. Ortho will be solely responsible for
Development of all Collaboration Products and, as a result, shall be responsible
for carrying out Development pursuant to the Development Plan including both
Ortho Development and GTx/Ortho Development. While Ortho is solely responsible
for Development, GTx agrees to carry out tasks under the Development Plan, if
any, reasonably assigned to it with respect to GTx/Ortho Development, pursuant
to the mutual agreement of the Parties.

         4.2 Development Plan.

                  (a) Development Carried Out Pursuant to Development Plan and
Development Budget. The Development of each Collaboration Compound shall be

                                       20



carried out pursuant to a development plan ("Development Plan") and development
budget ("Development Budget"). An outline of the Development activities the
Parties intend to carry out during 2004 and 2005 is attached as Exhibit C (the
"Initial Plan"). The Parties will agree upon a preliminary Development Plan and
Development Budget [ * ] after the Effective Date that sets forth the
Development activities to be performed by the Parties during 2004 and 2005,
together with a budget therefor. [ * ] after the Effective Date, such
Development Plan and Development Budget shall be expanded to include other
Development activities and related budgets to be conducted for Collaboration
Products. The Development Plan and Development Budget will be updated by Ortho
on an annual basis.

                  (b) GTx to Provide Ortho With Information Necessary for
Development. GTx shall provide Ortho with access to (and copies of, which may be
in partially or wholly electronic form, to the extent requested) all of the raw
data and reports related to the Development of any of the Collaboration
Compounds and/or Collaboration Products, including those Developed by the
GTx/Ortho Development and those Developed by the Ortho Development, provided
that in no event will GTx be obligated to provide to Ortho any such information
that relates also to compounds described in Section 1.36(1) but not Section
1.36(2), unless such information is reasonably necessary for the Development of
Collaboration Compounds.

                  (c) Content of Development Plan. The Development Plan shall
describe the proposed overall program of all the Development, including, but not
limited to, Pre-Clinical Studies, toxicology, formulation, chemical process
development, Clinical Studies, regulatory plans and other elements of obtaining
Regulatory Approval, and projected timelines for the Development events. The
Development Plan will specify Party-specific execution responsibilities of the
program expected during the Development (consistent with this Agreement) through
obtaining Regulatory Approval for each Collaboration Compound and/or
Collaboration Product, and shall further include a Development Budget for all
Development proposed. The Development Plan for the Development will identify
endpoints needed for initiation of the next phase of the Development.

         4.3 Development Efforts.

                  (a) In carrying out the Development and the Development Plan,
Ortho agrees to use the level of time, effort and funding as is consistent with
that expended on other Ortho projects at a similar stage of Development with a
target market of similar size and importance. Ortho's failure to comply with
such diligence obligations shall constitute a breach of this Agreement.

                  (b) Specifically, and without limiting Section 4.3(a), Ortho
shall use commercially reasonable efforts to conduct the activities set forth in
the Initial Plan.

         4.4 Drug Approval Applications. Consistent with the Development Plan,
Ortho shall be responsible for the filing of all Drug Approval Applications and
seeking Regulatory Approvals for Collaboration Compounds and/or Collaboration
Products. The

                                       21



Parties shall consult and cooperate in the preparation of each such Drug
Approval Application and in obtaining Regulatory Approvals. Ortho shall solely
own all Drug Approval Applications and Regulatory Approvals. [ * ] after GTx
provides Ortho with a top line summary of completion of the clinical trial that
GTx is currently conducting that it has deemed to be a Phase ID clinical trial
as described in the Initial Plan [ * ] (the "Phase ID Clinical Trial"), GTx
shall transfer or assign its ownership of IND No. [ * ] to Ortho or its
Affiliate as designated by Ortho, and shall take such other actions and execute
such other instruments, assignments and documents as may be necessary to effect
the transfer of rights hereunder to Ortho or its Affiliate as designated by
Ortho.

         4.5 Development Expenses.

                  (a) GTx Development Expenses. GTx's Development Expenses
incurred after the Effective Date in connection with its personnel's Development
efforts shall be calculated [ * ], and Development Expenses incurred by GTx
shall also include any amounts paid by GTx to Third Parties that otherwise
qualify as Development Expenses, which shall be reimbursed as provided in
subsection (b) below.

                  (b) Ortho to Reimburse GTx for Development Expenses. Ortho
shall reimburse GTx for its costs of conducting the Phase ID Clinical Trial that
GTx incurs prior to the Effective Date by paying to GTx an amount not to exceed
$ 687,000 within thirty (30) Business Days after receipt of an invoice. In the
event that GTx incurs any Development Expenses after the Effective Date, such
expenses shall initially be borne by GTx, subject to reimbursement as provided
herein. Each Party shall calculate and maintain records of Development Expenses
incurred by it. GTx shall report quarterly to Ortho its Development Expenses,
with such reports to be submitted within twenty (20) Business Days after the end
of each calendar quarter of each calendar year. The Parties shall seek to
resolve any questions related to such accounting statements within ten (10)
Business Days following receipt. Ortho shall reimburse GTx for any undisputed
Development Expenses GTx incurred within thirty (30) Business Days of receiving
the GTx report. If Ortho disputes its obligation to reimburse any Development
Expenses for which GTx seeks reimbursement hereunder, such dispute shall be
submitted for resolution pursuant to Article XV.

         4.6 Replacement Collaboration Compounds; Additional Collaboration
Compounds. At any time, Ortho may select a Collaboration Compound other than
Andarine for Development pursuant to this Agreement in addition to Andarine,
which shall be an Additional Collaboration Compound. Furthermore, if the Ortho
determines that further Development of Andarine or an Additional Collaboration
Compound, if any, is not desirable, then it may select another Collaboration
Compound to replace Andarine or such Additional Collaboration Compound (and such
replacement compound shall be a "Replacement Collaboration Compound"). In either
of the foregoing events, within forty-five (45) calendar days after the
selection of such Additional Collaboration Compound or Replacement Collaboration
Compound, then Ortho shall update the then-current Development Plan and
Development Budget to provide for Development of such compound.

                                       22



                                   ARTICLE V

                                    LICENSES

         5.1 Patent Licenses to Conduct Development.

                  (a) Subject to the terms and conditions of this Agreement, GTx
grants to Ortho an exclusive (except as to GTx), royalty-bearing, worldwide
license under the GTx Patents to conduct Development of Collaboration Products
pursuant to the Development Plan.

                  (b) Subject to the terms and conditions of this Agreement,
Ortho grants to GTx a non-exclusive, paid-up, worldwide license under the Ortho
Patents to conduct GTx's responsibilities under the Development Plan with
respect to Collaboration Products.

         5.2 Patent Licenses to Conduct Commercialization Activities.


                  (a) Subject to the terms and conditions of this Agreement, GTx
hereby grants to Ortho an exclusive (even as to GTx), royalty-bearing, worldwide
license, with the right to grant sublicenses, under GTx Patents for GTx SARM
Compounds to make, have made, use, sell, have sold, offer for sale, import,
export, and distribute Collaboration Products. Notwithstanding the foregoing,
GTx shall retain the right under the GTx Patents to Co-Promote Collaboration
Products in the Co-Promotion Territory to the GTx Audience if it exercises its
right to Co-Promote such Collaboration Products under Section 6.2.

                  (b) Subject to the terms and conditions of this Agreement,
Ortho hereby grants to GTx a non-exclusive, fully-paid, worldwide license,
without the right to grant sublicenses, under the Ortho Patents to use, sell,
and offer for sale Collaboration Products in the Co-Promotion Territory to the
GTx Audience if it exercises its right to Co-Promote such Collaboration Products
under Section 6.2.

         5.3 Know-how Licenses.

                  (a) Subject to the terms and conditions of this Agreement, GTx
grants Ortho, an exclusive (except as to GTx), royalty-bearing, worldwide
license to use GTx Know-how to Develop and/or Commercialize Collaboration
Products pursuant to the terms of this Agreement.

                  (b) Subject to the terms and conditions of this Agreement,
Ortho hereby grants to GTx a non-exclusive, fully-paid, worldwide license,
without the right to grant sublicenses, under the Ortho Know-How to perform its
obligations under the Development Plan to Develop Collaboration Products, and to
use, sell, and offer for sale Collaboration Products in the Co-Promotion
Territory to the GTx Audience if it exercises its right to Co-Promote such
Collaboration Products under Section 6.2.

                                       23



         5.4 Distribution Through Third Party Distributors. GTx grants Ortho the
right to sell or distribute Collaboration Products through its Affiliates or
Third Parties in any country, except as otherwise provided in Section 5.5.

         5.5 Sublicensing. Ortho may grant sublicenses under Sections 5.1, 5.2,
5.3 and 5.6 provided, however, that Ortho may not grant sublicenses or rights to
any Third Party (but may grant sublicenses or rights to its Affiliates) for the
purpose of selling, offering for sale, or distributing Collaboration Products in
the Co-Promotion Territory.

         5.6 Third Party Technology. The licenses granted under this Article
include sublicenses of Third Party technology to the extent that such
sublicenses can be so granted. To the extent the licenses include sublicenses of
Third Party technology, the licenses and rights granted to either Party under
such Third Party technology in any event, shall be subject to the terms and
conditions of the license agreement pursuant to which the underlying license,
and the sublicensing rights thereunder, were granted.

         5.7 No Implied Licenses; Retained Rights. Each Party retains all rights
under its Patents and know-how that are not expressly granted to the other Party
pursuant to this Agreement. Additionally, notwithstanding anything to the
contrary in this Article V, GTx retains the right under the GTx Patents and GTx
Know-how to use Collaboration Compounds and Collaboration Products in its
internal research and development efforts other than for the purpose of
Developing or Commercializing Collaboration Compounds or Collaboration Products,
which it shall perform only pursuant to this Agreement. Furthermore, Ortho
acknowledges that the licenses provided to it in Sections 5.1 through 5.3 do not
grant to Ortho any rights to practice the technology claimed in the GTx Patents
in connection with the development or commercialization of compounds that are
not Collaboration Compounds, including without limitation Excluded SARM
Compounds.

         5.8 Independent Research. Except with respect to the GTx SARM Compounds
defined in Section 1.36, each Party is free to develop other pharmaceutical
products independent of this Agreement, including without limitation, any other
SARM products that are not Collaboration Products. Neither Party has an
obligation to disclose information relating to medicinal chemistry or other
topics relating to SARMs, except to the extent such information may relate to
Collaboration Compounds or Collaboration Products.

                                   ARTICLE VI

                                COMMERCIALIZATION

         6.1 Ortho as Marketing Party. Ortho will be the marketing Party with
respect to all Collaboration Products. As marketing Party Ortho shall have full
and exclusive decision making authority with respect to all Commercialization
Activities for all Collaboration Products, provided that such decisions are
consistent with this Agreement and except as otherwise set forth in this
Agreement.

                                       24



         6.2 GTx's Option to Co-Promote in the United States. GTx shall have an
option to provide Details in the United States for each Collaboration Product
Developed pursuant to the GTx/Ortho Development to urologists who are licensed
to practice in the United States, provided that GTx meets the requirements set
forth in this Article VI, and subject to the provisions of Section 6.3 and 6.7.
Any such activities conducted by GTx pursuant to this Article VI, if GTx
exercises such option, shall be deemed "Co-Promotion." GTx may exercise its
option to Co-Promote on a Product by Product basis, and a decision not to
Co-Promote a specific Product shall not affect GTx's rights to Co-Promote any
other Product under this Agreement. However, if GTx fails to exercise its option
to Co-Promote any specific Product, or later terminates its Co-Promotion of such
Product, such non-exercise or termination shall be irrevocable as for such
Product. Additional Collaboration Products will be Co-Promoted under the same
terms as recited herein with respect to the first Collaboration Product.

         6.3 GTx to Notify Ortho of its Election to Co-Promote; Changes in the
GTx Audience.

                  (a) GTx may exercise its option by informing Ortho in writing
of its decision to exercise the Co-Promotion option for a Collaboration Product
[ * ] after [ * ]. Upon GTx's exercise of such option, the United States shall
become the Co-Promotion Territory with respect to such Collaboration Product,
GTx shall have the right to perform Details targeting the GTx Audience
(determined in accordance with Section 6.3(b)) with respect to such
Collaboration Product, and the provisions of Article VII shall be used in
determining additional compensation to be paid to GTx.

                  (b) GTx shall have the right to Co-Promote Collaboration
Products to all of the practicing urologists in the United States, and to elect
to include a portion of, or all of, such physicians in the GTx Audience, subject
to Section 6.7 and this Section 6.3. Within [ * ] after GTx first exercises its
right to Co-Promote, GTx shall provide to Ortho a list of urologists licensed to
practice in the United States that will constitute the GTx Audience, for Ortho's
approval thereof, which shall not be unreasonably withheld or delayed, and which
approval or disapproval shall be consistent with this Agreement. GTx shall
periodically [ * ] update the list of urologists that constitute the GTx
Audience, provided that any such change shall not become effective until [ * ]
after Ortho receives any updated list from GTx, and further provided that such
changes shall be in accordance with Section 6.3(c). Ortho shall have [ * ], and
[ * ] consistent with this Agreement. Except as provided in Section 6.7, GTx
shall have the exclusive right to provide Details for the GTx Audience.

                  (c) During the time GTx is Co-Promoting a Product, GTx shall
not have the right to alter the number of physicians included in the GTx
Audience for a given Product by [ * ] in any given [ * ] commencing after GTx
begins to Co-Promote such Product without Ortho's approval, which shall not be
unreasonably withheld or delayed and which shall be consistent with this
Agreement. GTx shall notify Ortho in writing of any such change in the number of
physicians included in the GTx Audience [ * ] before the end of any relevant [ *
] for which it desires such increase to apply. Additionally, if GTx has elected
to Co-Promote Products pursuant to this Article VI but has not

                                       25



performed its obligations under Section 6.6(a)(iv), and therefore has [ * ],
then GTx shall have the right to increase the proportion of the GTx Audience to
which it has the right to provide Details by [ * ] in each [ * ] following the [
* ] of GTx's commencement of Co-Promotion of such Products, provided that GTx
gives written notice to Ortho [ * ] before the end of any relevant [ * ] during
which it is then Co-Promoting such Product to less than all of the GTx Audience
stating the proportion of the GTx Audience by which GTx desires to increase its
Detailing efforts during the [ * ]. For clarity, GTx may only increase the
proportion of the GTx Audience to which it will Co-Promote if GTx has [ * ].

         6.4 Marketing and Sales Committee. Ortho and GTx will form a Marketing
and Sales Committee [ * ] to the first anticipated Launch Date. The Marketing
and Sales Committee shall meet from time to time [ * ], at mutual agreeable
times and locations, to discuss and coordinate the Marketing and Co-Promotion of
the Collaboration Product, including but not limited to, the assignment of
Details and to discuss the Marketing and Sales Plan. Ortho will have the final
responsibility (subject to GTx's rights to Co-Promote), with the cooperation and
assistance of GTx for defining the resources required for the marketing and sale
of the Collaboration Product, and for establishing Detailing, Marketing, pricing
and promotion strategies with respect to the Collaboration Product and budgets
therefor. Any disagreements or disputes arising from the Marketing and Sales
Committee shall be resolved in a matter consistent with [ * ] this Agreement.

         6.5 Marketing and Sales Plan. [ * ] to the first anticipated Launch
Date, Ortho shall prepare and present to the Marketing and Sales Committee for
its review and comment on a Marketing and Sales Plan. The Marketing and Sales
Plan shall set forth, among other items, Detailing and Marketing strategies for
each Collaboration Product, and shall specify the level of marketing efforts
anticipated for licensed urologists in the United States. The Marketing and
Sales Plan shall be updated at least annually by Ortho and presented to the
Marketing and Sales Committee for review and comment. The Marketing and Sales
Plan shall set the required number of Details to be provided by each of the
Parties (as applicable). Additionally, the Marketing and Sales Plan may not be
modified to provide for material increases in the number of Details to be
provided by GTx for Collaboration Products to be Co-Promoted by GTx in the [ * ]
following the effective date of such update without GTx's prior written consent.

         6.6 Requirements for GTx Co-Promotion. In order for GTx to be eligible
for Co-Promotion of a given Collaboration Product, GTx must meet the following
requirements:

                  (a) GTx shall have the following infrastructure in place for
each Collaboration Product at the following times:

                           (i) [ * ] after providing Ortho with written notice
of its intent to Co-Promote under Section 6.3, GTx shall [ * ];

                           (ii) [ * ] to the estimated Marketing Date (as
defined below in this Section 6.6) for the Collaboration Product, GTx must have
[ * ];

                                       26



                           (iii) [ * ] to the estimated Marketing Date for the
Collaboration Product, GTx must have [ * ]; and

                           (iv) [ * ] to the estimated Marketing Date for the
Collaboration Product, GTx must [ * ], and shall have [ * ].

                  (b) To enable GTx to plan its compliance with the requirements
of this Section 6.6, Ortho shall keep GTx informed of its good faith estimates
of the Marketing Date of each Collaboration Product in the United States. If any
such estimate provided by Ortho is subsequently modified so that the Marketing
Date is projected to occur earlier than previously estimated, then GTx shall not
be in breach of this Section 6.6 so long as it is using commercially reasonable
efforts to perform its obligations under this Section 6.6.

                  (c) "Marketing Date" shall mean, for a Collaboration Product,
either the Launch Date of such Collaboration Product, if such date has not
occurred prior to the time that GTx exercised its option to Co-Promote such
Product, or the first anticipated date upon which Ortho plans to commence its
marketing campaign for such Collaboration Product [ * ] for which the GTx
Audience may prescribe such products, if the Launch Date for such Collaboration
Product has previously occurred.

         6.7 Co-Promotion Sales Forces.

                  (a) If GTx exercises its option to Co-Promote a given
Collaboration Product, Ortho and GTx shall deploy their respective sales forces
to Detail the Collaboration Product as required by the Marketing and Sales Plan.
In conducting such Detailing, Ortho and GTx shall comply with all applicable
laws and shall use commercially reasonable efforts consistent with accepted
pharmaceutical industry business practices (including, but not limited to, the
relevant American Medical Association Guidelines). No Party shall be required to
undertake any activity under this Agreement which it believes, in good faith,
may violate any law. The GTx sales force shall abide by the same ethical conduct
guidelines as the Ortho sales force, including, but not limited to any
healthcare compliance guidelines issued by any U.S. government organization.

                  (b) The GTx sales force promoting Collaboration Products shall
include [ * ].

                  (c) GTx shall keep Ortho informed of the status of its efforts
to meet its Co-Promotion requirements. If GTx believes it will not meet the
requirements set forth in Section 6.6(a), GTx shall notify Ortho. If Ortho
believes that GTx has failed, or is likely to fail, to meet the foregoing
requirements, it shall so notify GTx in writing and the Parties shall thereafter
discuss whether any such failure has occurred, and appropriate steps and time
periods for GTx to thereafter cure any such failure, for a period of [ * ].
Resolution of any outstanding issues will be conducted through the Marketing and
Sales Committee pursuant to Section 6.4.

                           (i) Any failure by GTx to comply with the
requirements of Section 6.6 (other than subsection 6.6(a)(iv)) shall give rise
to Ortho's ability to terminate

                                       27



GTx's ability to Co-Promote the relevant Collaboration Product upon written
notice to GTx (which shall not become effective until expiration of the
foregoing discussion or cure period), but shall not be deemed to be a breach of
this Agreement giving Ortho the right to terminate this Agreement. In the event
of any failure by GTx to comply with subsection (iv), GTx shall continue to have
the right to Co-Promote Collaboration Products to the GTx Audience, but [ * ],
and Ortho may [ * ]. For example, if GTx [ * ], then it may [ * ] and Ortho may
[ * ]. In such event, after such [ * ], GTx shall have the right to [ * ],
provided that it has then [ * ], and further provided that [ * ].

         6.8 Sales Force Training. GTx sales representatives who will be
Co-Promoting Collaboration Product hereunder will be trained by Ortho together
with Ortho's sales representatives at a location to be determined by Ortho.
Ortho shall [ * ], provided that GTx shall [ * ].

         6.9 GTx Sales Force. All Detailing carried out hereunder by GTx shall
be [ * ]. Except as provided in Section 6.8, [ * ], including, but not limited
to, [ * ]. In addition, GTx shall, consistent with customary pharmaceutical
business practice and all applicable laws, rules and regulations, [ * ] in
accordance with the Marketing and Sales Plan. GTx may not [ * ], unless approved
in writing by Ortho in advance.

         6.10 Detail Reports. GTx, [ * ] after the end of each month, will
provide to Ortho on an electronic medium a record of its Detailing activity by [
* ]. This file will provide information on all Details [ * ], along with
information regarding samples, if any, that [ * ]. Once submitted to Ortho, such
Detail report described herein may not be revised by GTx and payments described
in Section 7.1 shall be based on the information contained in such Detail
report, subject, however, to revisions, if any, to the detail report from an
audit under Section 6.11.

         6.11 Co-Promotion Audit of Performance. Ortho shall have the right to
review and audit, not more than once per year, GTx's Detail records during
regular business hours, upon reasonable notice, to confirm satisfaction of the
obligations set forth in this Article VI. GTx may redact such records if
necessary to protect confidentiality of portions of such records unrelated to
Collaboration Products. Ortho shall provide to GTx a copy of the results of any
such audit. If, after such review, the Parties are unable to agree as to the
results of Ortho's audit, Ortho may demand a verification of such audit of GTx's
Detail reports to be conducted by a mutually agreed upon auditor, such
verification to be at Ortho's sole expense. In addition, Ortho representatives
may accompany GTx sales representative on Details to monitor their performance.
Furthermore, Ortho may audit GTx's Detailing performance using [ * ] or other
commercially developed service or product.

         6.12 Failure to Perform. If, based on the Detail reports GTx submits
(as revised based on any audit described in Section 6.11), GTx fails to conduct
[ * ] of the Details it is required to provide (taking into consideration the
adjustments to such level that GTx is permitted to make pursuant to Section
6.7(c)), as set forth in the Marketing and Sales Plan, for [ * ], it shall be
considered in breach of this Article VI and Ortho may terminate GTx's right to
Co-Promote hereunder by giving GTx thirty (30) calendar days'

                                       28



advance written notice of the termination of its Co-Promotion right hereunder.
However, such breach shall not be considered a material breach giving Ortho the
right to terminate this Agreement under Section 13.2.

         6.13 Medical Inquiries. Ortho shall respond to all medical questions or
inquiries relating to the Collaboration Product being Co-Promoted hereunder,
which are directed to each Parties' respective sales representatives, unless
such question or inquiry can be answered by reference to the FDA approved
labeling and package insert. Ortho shall designate a medical liaison to whom GTx
shall instruct the GTx sales force to direct medical questions or inquiries
relating to the Co-Promoted Collaboration Product.

         6.14 Governmental Contact. GTx shall notify Ortho's Regulatory Affairs
Department upon being contacted by the FDA or any state drug regulatory agency
or any comparable governmental agency in the Co-Promotion Territory with respect
to the Co-Promoted Collaboration Product. Ortho shall retain responsibility for
communicating with all such governmental agencies and responding to any contacts
or inquiries of such agencies.

         6.15 Regulatory Disputes/Lawsuits. Ortho shall retain exclusive
authority and responsibility for handling, in any manner it deems appropriate,
any disputes or law suits with any agencies regarding the regulatory status of
the Co-Promoted Collaboration Product.

         6.16 Sales. All sales of Collaboration Products in the Co-Promotion
Territory shall be booked by Ortho. Ortho shall have the right to reject any
order received by it for a Collaboration Product; provided, however, that Ortho
shall not reject orders on an arbitrary basis, but only with reasonable
justification and consistent with the general policies applied by it with
respect to orders for other similar pharmaceutical products sold by it.

         6.17 Orders. A sales representative's only in-state activity is
solicitation of orders by company representatives for sales of tangible personal
property, which orders are sent outside the state (except NJ) for approval or
rejection and if approved, are filled by shipment or delivery from a point
outside the state (except NJ). "Solicitation of Orders" is defined as
encompassing "requests for purchases" as well as "those activities that are
ancillary to requests for purchases, those that serve no independent business
function apart from their connection to the soliciting of orders. GTx is not
authorized to solicit or accept any sales orders for the Co-Promoted
Collaboration Products. If, for any reason, GTx receives a sales order for the
Co-Promoted Collaboration Product, GTx shall promptly forward such orders to
Ortho.

         6.18 Co-Promotion Limitation of Scope. The scope of the Co-Promotion
for GTx will be limited specifically to [ * ]. The Marketing and Sales Plan
shall set the required number of Details for each of the Parties.

         6.19 Commercialization Efforts. Ortho shall use reasonable efforts
consistent with its normal business practices to Commercialize the Collaboration
Product in those

                                       29



countries in which it has obtained Regulatory Approval. Without limiting the
foregoing, Ortho shall effect a Marketing Date in the United States [ * ] of
obtaining Regulatory Approval of a Collaboration Product by the FDA.

         6.20 Commercialization in Royalty Bearing Territory. Commercialization
of Collaboration Products in the Royalty Bearing Territory, except to the extent
of GTx's right to Co-Promote Collaboration Products to the GTx Audience, shall
be conducted independently by Ortho and decisions regarding, for example,
pricing, advertising, and product recalls shall be the sole responsibility of
Ortho.

         6.21 Pricing, Pricing Approvals and Product Distribution. Ortho shall
set all prices for all Collaboration Products in all territories, shall obtain
pricing and reimbursement approvals for Collaboration Products as may be
required, shall be responsible for distribution of each Collaboration Product
worldwide Territory and shall book all sales for Collaboration Products.

         6.22 Product Recalls. If Ortho believes that a recall of a
Collaboration Product is necessary, Ortho shall promptly undertake, at its sole
expense, such recall following notification to GTx. The decision of Ortho
concerning such recall shall be final.

         6.23 Advertising and Promotion. With respect to printed promotional
(including all advertisements and DTC-programs appearing in journals) materials
or printed educational materials for Collaboration Products, Ortho shall be
solely responsible for the content of such materials and the preparation
thereof, at Ortho's sole expense.

         6.24 GTx Right to Opt Out of Co-Promotion. At any time after it
exercises its option to Co-Promote a given Collaboration Product, GTx may elect
by [ * ] advance written notice to Ortho to cease Co-Promotion of such
Collaboration Product. After any such election by GTx, GTx shall cooperate with
Ortho to transition responsibility for providing Details to the GTx Audience for
such Collaboration Product to Ortho. GTx's rights under this Section 6.24 shall
apply on a product by product basis.

         6.25 Additional Support by GTx. If Ortho desires GTx to participate in
Marketing Activities other than providing Details for Collaboration Products,
such as by [ * ], the Parties shall discuss the proposed activities. If GTx
agrees in writing to conduct such activities, the Marketing and Sales Plan shall
be revised to reflect such activities [ * ].

                                       30



                                   ARTICLE VII

                              CO-PROMOTION PAYMENT

         7.1 Additional Royalty. For any Collaboration Product that is
Co-Promoted by GTx to the GTx Audience, GTx shall at a minimum first earn a
royalty as set forth in Section 3.4 in the Co-Promotion Territory. GTx shall
also earn an Additional Royalty with respect to sales of Collaboration Products
that GTx Co-Promotes, which will be calculated as follows:

                  (a) Twenty (20) Business Days after the end of each calendar
quarter, Ortho will determine, using data obtained from Third Party sources
reasonably acceptable to GTx, the total number of prescriptions written for the
Collaboration Product(s) by the GTx Audience and filled by the pharmacy during
the preceding quarter, and shall provide to GTx a detailed calculation of the
royalty due to GTx pursuant to this Section 7.1 along with a copy of the Third
Party information upon which such calculation is based. Ortho shall pay all
royalties due to GTx pursuant to this Section 7.1 within twenty (20) Business
Days after submission of such report to GTx.

                  (b) The following formula will be used to calculate the
Additional Royalty owed to GTx for the preceding quarter:


                      [ * ]

wherein

                      [ * ]

         The Additional Royalty shall not be subject to any offsets or
reductions that may be applicable to royalties due to GTx pursuant to Section
3.4. GTx shall have the right to audit Ortho's records to confirm the accuracy
of payments made hereunder as provided in Section 12.4.

         7.2 Term. Ortho shall pay the Additional Royalty as provided under this
Article 7 with respect to each Collaboration Product Co-Promoted in the
Co-Promotion Territory to the GTx Audience until such Collaboration Product is
permanently withdrawn from, or is no longer being Co-Promoted in, the
Co-Promotion Territory.

                                  ARTICLE VIII

                             MANUFACTURE AND SUPPLY

         8.1 Manufacture and Supply During Development. Ortho will be solely
responsible for the manufacture of Collaboration Products for use during the
Development of Collaboration Products as provided in this Agreement, except that
following the Effective Date, GTx shall remain responsible for the manufacture
of Collaboration Products until the Parties transition to Ortho responsibility
for the manufacture of Collaboration Products, or components thereof, for which
GTx has been

                                       31



responsible prior to the Effective Date. Promptly following the Effective Date,
the Parties shall agree upon and implement a plan for effecting such transition,
which may include without limitation GTx continuing to be a party to Third Party
manufacturing agreements existing as of the Effective Date for the remainder of
the term of such agreements, or GTx assigning to Ortho (if it is permitted to do
so under the relevant agreement) its interest in such agreements; provided that
if any such agreement also relates to the supply of products other than
Collaboration Products, then GTx shall have no obligation to effect any such
assignment. In this regard, Ortho and not GTx shall be a party to all future
manufacturing agreements with Third Parties for the supply of Collaboration
Products during Development. Payments to manufacturers of Collaboration Products
for Development purposes and related costs will be [ * ]. For clarity, if GTx [
* ] after the Effective Date for such purpose, then Ortho shall [ * ]. As used
in this Article, "manufacture" means manufacture of Collaboration Products in
bulk form and finished dosage form.

         8.2 Manufacture and Supply During Commercialization. Ortho shall be
solely responsible for the commercial manufacture of Collaboration Products in
such a manner as to assure quality assurance as stringent as such quality
assurance standards used by Ortho and its Affiliates in the manufacture of its
other pharmaceutical products, continuity and security of supply, compliance
with cGMP, and compliance with all applicable regulatory requirements. In this
regard, Ortho shall be a party to all agreements covering the commercial supply
of Collaboration Products. Such manufacturer(s) may include Third Parties.

         8.3 Clinical Supplies. In cases where GTx supplies Ortho with
Collaboration Compound or Collaboration Product for clinical studies, such
supplies will be provided [ * ].

         8.4 Quality Assurance. Ortho shall also have day to day responsibility
for commercial manufacturing and formulation issues related to product safety
and regulatory compliance. GTx shall provide technical support reasonably
required by Ortho or Third Parties for the manufacture of Collaboration
Products. Ortho shall [ * ].

         8.5 Technology Transfer in Event of Termination by Ortho. In the event
that this Agreement terminates (other than for a Material Breach by GTx), then
Ortho shall continue to manufacture and supply (either itself or through its
Affiliates or Third Parties) Collaboration Products in the manner and to the
extent provided prior to notice of such termination, from the time notice of
such termination is provided until such time as GTx is able to secure an
equivalent alternative commercial manufacturing source; said time [ * ],
provided that GTx using its commercially reasonable efforts is unable to secure
such an alternative source during such time period. To this end, as of the
effective date of such termination, Ortho shall use commercially reasonable
efforts to [ * ]. For any Collaboration Products supplied by Ortho or its
Affiliates, [ * ] pursuant to this Section for the [ * ] shall [ * ]. Such [ *
]. For example, [ * ]. If termination is the result of a serious Safety issue,
Ortho shall not be obligated to continue manufacturing the Collaboration Product
associated with the serious Safety issue.

                                       32



                                   ARTICLE IX

                                 CONFIDENTIALITY

         9.1 Confidentiality Exceptions. Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that, for the term of this Agreement and for [ * ] thereafter, the receiving
Party shall keep confidential and shall not publish or otherwise disclose or use
for any purpose other than as permitted in this Agreement any Information and
other information and materials furnished to it by the other Party pursuant to
this Agreement; any provisions of this Agreement that are the subject of an
effective order of the Securities Exchange Commission granting confidential
treatment pursuant to the Securities Act of 1934, as amended; and any
Information developed during the term of, and pursuant to, this Agreement
(collectively, "Confidential Information"), except to the extent that it can be
established by the receiving Party that such Confidential Information:

                  (a) was already known to the receiving Party, other than under
an obligation of confidentiality, at the time of disclosure by the other Party;

                  (b) was generally available to the public or otherwise part of
the public domain at the time of its disclosure to the receiving Party;

                  (c) became generally available to the public or otherwise part
of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement;

                  (d) was disclosed to the receiving Party, other than under an
obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others; and

                  (e) was independently developed by the receiving Party without
reliance on Confidential Information of the other Party as shown by documentary
evidence.

         9.2 Authorized Disclosure.

                  (a) Each Party may disclose Confidential Information hereunder
to the extent such disclosure is reasonably necessary in filing or prosecuting
patent applications, prosecuting or defending litigation, complying with
applicable governmental regulations, or conducting Pre-Clinical Studies or
Clinical Trials; provided, however, that if a Party is required by law or
regulation to make any such disclosures of the other Party's Confidential
Information it will, except where impracticable for necessary disclosures, for
example in the event of medical emergency, give reasonable advance notice to the
other Party of such disclosure requirement (e.g., filings with the SEC and stock
markets) and, except to the extent inappropriate in the case of patent
applications, will use its reasonable efforts to secure confidential treatment
of such Confidential Information required to be disclosed, unless in the opinion
of such disclosing Party's legal counsel such Confidential Information is
legally required to be fully disclosed. In addition, and

                                       33



with prior notice to the other Party of each Third Party with whom a
confidential disclosure agreement is being entered into, each Party shall be
entitled to disclose, under a binder of confidentiality containing provisions as
protective as those of this Article, Confidential Information to any Third Party
for the purpose of carrying out the purposes of this Agreement. Nothing in this
Article shall restrict any Party from using for any purpose any Confidential
Information independently developed by it without access to or use of the other
Party's Confidential Information during the term of this Agreement, or from
using Confidential Information that is specifically derived from Pre-Clinical
Studies or Clinical Studies to perform marketing, sales or professional services
support functions as is customary in the pharmaceutical industry.

                  (b) Notwithstanding anything herein to the contrary, either
Party (and any employee, representative, or other agent of either Party) may
disclose to any and all persons, without limitation of any kind, the tax
treatment and tax structure of the transactions contemplated by this Agreement
and all materials of any kind (including opinions or other tax analyses) that
are provided to it relating to such tax treatment and tax structure; provided
however, that such disclosure shall not be made to the extent reasonably
necessary to comply with any applicable federal or state securities laws. For
the purposes of the foregoing sentence, (i) the "tax treatment" of a transaction
means the purported or claimed federal income tax treatment of the transaction,
and (ii) the "tax structure" of a transaction means any fact that may be
relevant to understanding the purported or claimed federal income tax treatment
of the transaction.

         9.3 Survival. Sections 9.1 through 9.4 of this Article shall survive
the termination or expiration of this Agreement for a period of [ * ].

         9.4 Termination of Prior Agreement. This Agreement supersedes the
Confidentiality Agreement between GTx and Ortho dated October 8, 2002 and
amended on June 2, 2003. All Information exchanged between the Parties under
that Agreement shall be deemed Confidential Information and shall be subject to
the terms of this Article, and shall be included, respectively, within the
definitions of GTx Know-how if GTx is the disclosing Party and Ortho Know-how if
Ortho is the disclosing Party.

         9.5 Publications. Except to the extent set forth in Sections 9.2 and
9.6, each Party shall provide to the other the opportunity to review any
proposed scientific/technical publications or scientific presentations which
relate to Collaboration Compounds or Collaboration Products as early as
reasonably practical, but [ * ] to the intended submission for publication
(except with the written consent of the other Party). The reviewing Party will
provide the publishing Party with its response to the publishing Party's request
to publish [ * ] of receipt of such request. No publication shall be made by any
Party without the written agreement of or approval by the other Party. However,
the failure of the receiving Party to respond to such request [ * ] period shall
be deemed to be approval of such request and the publishing Party shall then be
free to proceed with said publication or presentation. Notwithstanding the
foregoing, publications regarding Commercialization Activities or that are
reasonably needed to effectively Commercialize the Collaboration Product may be
made by Ortho even if GTx does not approve, provided

                                       34



that GTx may request a reasonable delay on such publication to seek patent
protection on any patentable inventions disclosed therein.

         9.6 Public Disclosures. Subject to the further provisions of this
Section, neither Party shall originate any written publicity, news release or
public announcement, whether to the public or press, concerning this Agreement,
including the subject matter to which it relates, performance under it or any of
its terms, or any amendment hereto save only such announcements that are
required by law (or the applicable rules of any securities exchange or market on
which a Party's securities are listed or traded) to be made or that are
otherwise agreed by the Parties or expressly permitted in this Agreement. Such
announcements shall be factual and as brief as reasonable under the
circumstances. In addition, each Party agrees to submit to the other Party, for
review and written approval, any question and answer sheet or similar materials
("Q & A") prior to using such materials as the basis for written or oral
disclosures, which written or oral disclosures must, in any event, be consistent
in content with the information contained in the approved Q & A. Routine
references to this Agreement and the arrangements hereunder shall be allowed in
the usual course of business, and shall be consistent with any approved Q & A
relating thereto. Once information has been approved for disclosure as part of
an approved Q & A or publication under this Section, either Party may use such
approved information in written publicity, news releases, public announcements
and other future communications with Third Parties. If a Party decides to make
an announcement or any filing with a governmental agency or securities exchange
or market as required by law or the applicable rules of any securities exchange
or market on which a Party's securities are listed or traded, it will give the
other Party [ * ] advance notice, where possible, of the text of the
announcement or content of the filing so that the other Party will have an
opportunity to comment upon the announcement or filing. To the extent that the
receiving Party reasonably requests that any information in the materials
proposed to be disclosed be maintained as confidential, the disclosing Party
shall use commercially reasonable efforts to request confidential treatment of
such information pursuant to Rule 406 of the Securities Act of 1933 or Rule
25b-2 of the Securities Exchange Act of 1934, as applicable (or any other
applicable regulation relating to the confidential treatment of information),
except to the extent that the disclosing Party receives advice from its legal
counsel that such Confidential Information is required to be disclosed under
applicable laws or regulations. Notwithstanding the foregoing, publications
regarding [ * ] may be made by Ortho even if GTx does not approve.

                                   ARTICLE X

              OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS

         10.1 Ownership. Each Party shall solely own, and that Party alone shall
have the right to apply for, Patents within and outside of the United States for
any inventions made solely by that Party's employees or independent contractors
in the course of performing work under this Agreement. Inventions made jointly
by employees or independent contractors of GTx and Ortho shall be owned jointly
by GTx and Ortho, without a duty of accounting. For clarity, either Party shall
be free to grant licenses or other rights under Inventions jointly owned by the
Parties, to the extent consistent with

                                       35



the licenses granted to the other Party pursuant to this Agreement. The law of
joint ownership of inventions of the United States shall apply to any joint
ownership of Patents claiming joint inventions of the Parties.

         10.2 Invention Disclosures. Each Party shall promptly provide to the
other any invention disclosure submitted in the normal course of its operations
and disclosing an invention arising during the course of and pursuant to this
Agreement (such inventions, "Inventions").

         10.3 Disclosure of Provisional and Non-Provisional Patent Applications.
In addition to the disclosures required under Article XII, each Party shall
provide to the other, within a reasonable time prior to filing, a copy of each
non-provisional patent application proposed to be filed by such Party disclosing
an Invention arising during the course of and pursuant to this Agreement and
each Party shall provide to the other, immediately after filing, a copy of each
provisional patent application actually filed by such Party disclosing an
Invention. The contents of any patent application submitted to either Party
pursuant to this Section 10.3 covering an invention solely owned by such Party
shall be deemed the Confidential Information of the Party providing such
application.

         10.4 Patent Filings.

                  (a) Ortho Patent, GTx Patent and Joint Patent Filings. Each
Party, at its sole discretion, responsibility, and cost shall prepare, file,
prosecute and maintain Patents to cover Inventions made solely by its own
employees or independent contractors and use reasonable efforts to file
initially all such applications in the United States or the appropriate forum
under the circumstances. Ortho shall file, prosecute and maintain Patents to
cover Inventions relating to the discovery, evaluation, manufacture, use or sale
of Collaboration Compounds or Collaboration Products that are made jointly by
employees or independent contractors of GTx and Ortho and the JDC shall select
the Party that shall be responsible for filing, prosecuting and maintaining
patent applications and other Patents claiming other jointly owned Inventions
(all Patents or jointly owned Inventions, herein referred to as "Joint
Patents"). [ * ]. The determination of the countries in which to file Joint
Patents shall be made [ * ]. The Party responsible for filing a Joint Patent
shall have the right to direct and control all material actions relating to the
prosecution or maintenance of Joint Patents, subject to the other Party's
ability to comment on such filings and the filing Party's reasonable
consideration of such comments. The Party responsible for filing a Joint Patent
shall provide prior written notice to the other Party of the countries in which
it intends to file, including conflict proceedings, reexaminations, reissuance,
oppositions and revocation proceedings, provided, however, that such other Party
shall have the right to file or continue prosecution in countries in which the
filing Party determines it wishes to abandon or not file such Joint Patent.

                  (b) Ortho and GTx Patent Strategy. Each Party shall keep the
other Party apprised of the status of each Joint Patent for which it is
responsible and shall seek the advice of such other Party with respect to patent
strategy and drafting applications

                                       36



and shall give reasonable consideration to any suggestions or recommendations
concerning the preparation, filing, prosecution, maintenance and defense
thereof. The Parties shall cooperate reasonably in the prosecution of all Joint
Patents and other GTx Patents or Ortho Patents covering Collaboration Products
and shall share all material information relating thereto, including all
material communications from patent offices, promptly after receipt of such
information. If the Parties are unable to agree as to who is the filing Party or
as to any aspect of patent prosecution of a Joint Patent or a Patent covering a
Collaboration Product, each Party at its expense shall be free to take whatever
action it deems appropriate to protect the joint Invention or Collaboration
Product, including the filing of patent applications subject to prior
notification of the other Party. If, during the term of this Agreement, the
filing Party intends to allow any Patent covering a Product to which the Party
has license rights under this Agreement to lapse or become abandoned without
having first filed a substitute, the filing Party shall, whenever practicable,
notify the other Party of such intention [ * ] to the date upon which such
Patent shall lapse or become abandoned, and the other Party shall thereupon have
the right, but not the obligation, to assume responsibility for the prosecution,
maintenance and defense thereof and all expenses related thereto.

                  (c) Diligence in Patent Filings. The Parties agree to use
reasonable efforts to ensure that any Patent filed outside of the United States
prior to a filing in the United States will be in a form sufficient to establish
the date of original filing as a priority date for the purposes of a subsequent
filing in the United States.

                  (d) Cooperation by Ortho and GTx in Patent and Regulatory
Filings. The Parties shall cooperate in order to avoid loss of any rights that
may otherwise be available to the Parties under the U.S. Drug Price Competition
and Patent Term Restoration Act of 1984, the Supplementary Certificate of
Protection of the Member States of the European Union and other similar measures
in any other country. Without limiting the foregoing, Ortho shall notify GTx
upon receipt of Regulatory Approval to market a Collaboration Compound or
Collaboration Product in the United States, and timely supply GTx with all
information necessary to file an application for patent term extension for a
relevant GTx Patent, [ * ] following Regulatory Approval. GTx agrees to timely
file any such application, unless it reasonably objects to seeking such
extension for such Patent (in which case the dispute shall be resolved pursuant
to Article XV). The obligations set forth in this Section shall apply with
respect to patent term extensions, or the equivalent, in any other country. Any
application for patent term extension in the United States shall be made by the
Party who Controls the relevant patent.

         10.5 Third Party Patent Rights. Except as expressly provided in Section
11.1, neither Party makes any warranty with respect to the validity, perfection
or dominance of any Patent or other proprietary right or with respect to the
absence of rights in Third Parties which may be infringed by the manufacture or
sale of any Product. Each Party agrees to bring to the attention of the other
Party any Patent or Patent application it discovers, or has discovered, and
which relates to GTx SARM Compounds.

                                       37



         10.6 Enforcement Rights.

                  (a) Notification of Infringement. If either Party learns of
any infringement or threatened infringement by a Third Party of the GTx Patents
or Ortho Patents, such Party shall promptly notify the other Party and shall
provide such other Party with all available evidence of such infringement.

                  (b) Enforcement. GTx shall have the right, but not the
obligation, to institute, prosecute and control at its own expense any action or
proceeding with respect to infringement by any Third Party of any GTx Patents
(other than Joint Patents) covering the manufacture, use, importation,
exportation, sale or offer for sale of Collaboration Products by reason of the
manufacture, use or sale of products competitive with Collaboration Products,
using counsel of its own choice. Ortho shall have the right, at its own expense,
to be represented in any such action by counsel of its own choice. If GTx fails
to bring such an action or proceeding or otherwise take appropriate action to
abate such infringement [ * ] of notice by Ortho to GTx requesting action, Ortho
will have the right but not the obligation to bring and control, at its expense,
any such action or proceeding relating to GTx Patents by counsel of its own
choice and GTx will have the right to be represented in any such action by
counsel of its own choice and at its own expense. With respect to Ortho Patents
(including Joint Patents), Ortho shall have the right, but not the obligation,
to institute, prosecute and control at its own expense any action or proceeding
with respect to infringement by any Third Party of any Joint Patents or Ortho
Patents covering the manufacture, use, importation, exportation, sale or offer
for sale of Collaboration Products by reason of the manufacture, use or sale of
products competitive with Collaboration Products, using counsel of its own
choice. GTx shall have the right, at its own expense, to be represented in any
such action by counsel of its own choice in connection with any such litigation.
If one Party brings any such action or proceeding, the other Party agrees to be
joined as a party plaintiff if necessary to prosecute the action or proceeding
and to give the first Party reasonable assistance and authority to file and
prosecute the suit. If any GTx Patent or Ortho Patent (other than a Joint
Patent) is infringed other than by the manufacture, use or sale of products
competitive with Collaboration Products, then the Party Controlling such Patent
shall be free to seek to terminate such infringement without obligation to the
other Party. If a Joint Patent is infringed other than by the manufacture, use
or sale of a product competitive with a Collaboration Product, the Parties shall
discuss whether to proceed in terminating such infringement jointly, but in the
absence of their agreement to do so, either Party may seek to terminate such
infringement.

                  (c) Settlement with a Third Party. The Party that controls the
prosecution of a given action shall also have the right to control settlement of
such action; provided, however, that if one Party controls such action, no
settlement shall be entered into without the written consent of the other Party
if such settlement would materially and adversely affect the interests of such
other Party. If the other Party shall refuse to grant such consent, then the
dispute will be resolved pursuant to Article XV.

                  (d) Damage Award or Settlement Payments. Any damage award or
settlement payments made to either or both of GTx or Ortho in connection with
any such

                                       38



action relating to infringement of a GTx Patent or an Ortho Patent, whether
obtained by judgment, settlement or otherwise shall be allocated, (i) first, [ *
], (ii) second, to [ * ], and (iii) third, [ * ].

         10.7 Defense and Settlement of Third Party Claims. If a Third Party
asserts that a patent, trademark or other intangible right owned by it is
infringed by the manufacture, use, or sale of any Collaboration Product, Ortho
will be solely responsible for defending against any such assertions at its cost
and expense, but no settlement may be entered into without the written consent
of GTx if such settlement would materially and adversely affect GTx's interests
or the GTx Patents.

         10.8 Allocation of Patent Expenses. On a country-by-country basis,
Patent Expenses arising from GTx Patents shall be borne [ * ], Patent Expenses
arising from Ortho Patents shall be borne [ * ], and Patent Expenses arising
from Joint Patents shall be borne [ * ], unless otherwise agreed.

         10.9 Assignment of Joint Patents. Neither Party may assign its rights
under any Joint Patent except with the prior written consent of the other Party;
provided, however, that either Party may assign such rights without consent to
an Affiliate or other permitted assignee under this Agreement in connection with
a merger or similar reorganization or the sale of all or substantially all of
its assets.

         10.10 Trademarks and Trademark Expenses. Ortho shall be solely
responsible for the selection, registration, and maintenance of all trademarks
which it employs in connection with the marketing, promotion and sale of
Collaboration Product(s) and shall solely own and control such trademarks in the
Royalty Bearing Territory. Each Party recognizes the exclusive ownership by the
other Party of any proprietary names, logotypes or trademarks furnished by it
(including its Affiliates) that are not specific to Collaboration Products for
use exclusively in connection with Collaboration Products. Either Party shall
not, either while this Agreement is in effect, or at any time thereafter,
register, use or attempt to obtain any right in or to any such name, logotype or
trademark of the other Party or in and to any name, logotype or trademark
confusingly similar to the other Party's.

                                   ARTICLE XI

                         REPRESENTATIONS AND WARRANTIES

         11.1 Representations and Warranties.

                  (a) Parties' Representations and Warranties. Each of the
Parties hereby represents and warrants to the other Party as follows:

                           (i) Parties' Authority to Enter Into Agreement. This
Agreement is a legal and valid obligation binding upon such Party and
enforceable in accordance with its terms. The execution, delivery and
performance of the Agreement by such Party does not conflict with any agreement,
instrument or understanding, oral or written, to which it is a Party or by which
it is bound, nor violate any law or regulation of

                                       39



any court, governmental body or administrative or other agency having
jurisdiction over it. Each Party expressly represents and warrants that it has
the full power and authority to enter into this Agreement and to carry out the
obligations contemplated hereby.

                           (ii) Parties Will Not Provide Third Parties With
Conflicting Rights. Such Party has not, and during the term of the Agreement
will not, grant any right to any Third Party under its Patents and know-how that
are licensed to the other Party pursuant to this Agreement which would conflict
with the licenses granted to the other Party hereunder.

                           (iii) GTx Prior Obligations. To the best of its
knowledge, GTx is obligated under only the UTRF Agreements to pay to any Third
Party royalties with respect to Collaboration Products [ * ].

                  (b) GTx Representations and Warranties to Ortho. GTx hereby
represents and warrants to Ortho as follows:

                           (i) Validity of GTx Patents. As of the Effective
Date, GTx has supplied Ortho with all information known to GTx and in GTx's
possession that relates to the validity of the issued GTx Patents.

                           (ii) Infringement. As of the Effective Date, it has
not received any notices of infringement or any written communications relating
in any way to a possible infringement with respect to Andarine, and it is not
aware that the manufacture, use or sale of Andarine as set forth herein
infringes any Third Party patent rights which have not been licensed to GTx.

                           (iii) GTx's Power and Authority. GTx expressly
represents and warrants that it has the full power and authority to enter into
this Agreement and to carry out the obligations contemplated hereby. GTx
expressly represents and warrants that it owns (in whole or in part) or
otherwise Controls all Patents and know-how that are the subject of the licenses
granted to Ortho herein.

         11.2 Performance by Affiliates. The Parties recognize that each Party
may perform some or all of its obligations under this Agreement through
Affiliates, provided, however, that each Party shall remain responsible for and
be a guarantor of the performance by its Affiliates and shall cause its
Affiliates to comply with the provisions of this Agreement in connection with
such performance.

                                  ARTICLE XII

                             INFORMATION AND REPORTS

         12.1 Information and Reports During Development and Commercialization.
Ortho and GTx will disclose and make available to each other upon written
request and without charge (other than reimbursement to the providing Party for
reasonable duplicating, postage and related expenses) all pre-clinical,
clinical, regulatory, commercial, marketing, promotion, pricing, sales and other
Information, including copies

                                       40



of all preclinical and clinical reports, known by Ortho or GTx that directly
concern Collaboration Compounds or Collaboration Products, as provided for in
this Agreement. Each Party will use commercially reasonable and diligent efforts
to disclose to the other Party all significant Information relating to
Collaboration Compounds or Collaboration Products promptly after it is learned
or its significance is appreciated. Ortho shall [ * ]. Without limitation of the
foregoing, each Party shall supply to the other the Information required by the
other Party and reasonably requested by it (either as a routine practice or as a
specific request) for purposes of compliance with regulatory requirements
relating to Collaboration Compounds or Collaboration Products.

         12.2 Complaints. Each Party shall maintain a record of all complaints
it receives with respect to any Collaboration Product. Each Party shall notify
the other Party of any complaint with regulatory implications received by it in
sufficient detail and [ * ] after the event, and in any event in sufficient time
to allow the responsible Party to comply with any and all regulatory
requirements imposed upon it in any country.

         12.3 Adverse Event Reporting. The Parties recognize that Ortho as the
holder of Drug Approval Applications for Collaboration Products may be required
to submit information and file reports to various governmental agencies on
Collaboration Products under clinical investigation, Collaboration Products
proposed for marketing, or marketed Collaboration Products. Such information
must be submitted at the time of initial filing for investigational use in
humans and at the time of a request for Regulatory Approval of a new
Collaboration Product. In addition, Ortho may be required to provide
supplemental information on Collaboration Products at periodic intervals and to
report adverse drug experiences at more frequent intervals depending on the
severity of the experience and whether or not the event is unexpected. GTx will
(a) provide Ortho with all adverse event information and Safety-related data
from pre-clinical laboratory, animal toxicology, and pharmacology studies, and
Clinical Studies, in its Control that are necessary for Ortho to comply with all
applicable laws with respect to the Products, and (b) report and provide such
information to Ortho in such a manner and time so as to enable Ortho to comply
with all applicable laws. Each Party shall adhere to the adverse event reporting
procedures set forth in Exhibit B.

         12.4 Records of Revenues and Expenses.

                  (a) Maintenance; Audits. Each Party shall keep complete and
accurate records which are relevant to revenues, costs, reimbursements and other
payments to be made under this Agreement, including, without limitation,
information used to calculate Net Sales, Royalty Bearing Sales and royalty
calculations, existing Third Party royalty payments due for licenses granted by
such Third Parties, other license fees and other payments and royalties due
under this Agreement. Such records shall be open at the location(s) where such
records are maintained, upon reasonable notice, during regular business hours
and under obligations of confidence, [ * ]. The inspecting Party may examine
such records at its expense (not more often than once each year) by an
independent, certified public accountant, reasonably acceptable to the other
Party, for the sole purpose of verifying for the inspecting Party the accuracy
of calculations, amounts and classifications of such revenues, costs or payments
made under this Agreement. In

                                       41



the absence of material discrepancies (i.e., in those instances where
discrepancy [ * ] the amounts payable under this Agreement) identified in any
such audit, the accounting expenses shall be paid by the Party requesting the
audit. If material discrepancies are identified, the audited Party shall bear
all accounting expenses. If the review of such records reveals that the audited
Party has failed to accurately report information, then the relevant Party shall
promptly pay any amounts due to the inspecting Party together with interest on
such amount, calculated at a rate equal to [ * ] Any records or accounting
information received by a Party from the other Party shall be Confidential
Information for purposes of Article IX. Results of any such audit shall be
provided to both Parties, subject to Article IX. Audits of Detail reports shall
be governed by Section 6.11 and not by this Section 12.4.

                  (b) Audit Disagreement. If there is a dispute between the
Parties following any audit performed pursuant to Section 12.4(a), either Party
may refer the issue (an "Audit Disagreement") to an independent certified public
accountant for resolution. In the event an Audit Disagreement is submitted for
resolution by either Party, the Parties shall comply with the following
procedures:

                           (i) The Party submitting the Audit Disagreement for
resolution shall provide written notice to the other Party that it is invoking
the procedures of this Section.

                           (ii) Within thirty (30) calendar days of the giving
of such notice, the Parties shall jointly select a recognized international
accounting firm to act as an independent expert to resolve such Audit
Disagreement.

                           (iii) The Audit Disagreement submitted for resolution
shall be described by the Parties to the independent expert, which description
may be in written or oral form, within ten (10) calendar days of the selection
of such independent expert.

                           (iv) The independent expert shall render a decision
on the matter as soon as practicable.

                           (v) The decision of the independent expert shall be
final and binding and shall not be subject to Article XV hereof, unless such
Audit Disagreement involves alleged fraud, breach of this Agreement or
construction or interpretation of any of the terms and conditions hereof.

                           (vi) All fees and expenses of the independent expert,
including any Third Party support staff or other costs incurred with respect to
carrying out the procedures specified at the direction of the independent expert
in connection with such Audit Disagreement, shall be borne by the Party against
whom such expert rules.

                                       42



                                  ARTICLE XIII

                              TERM AND TERMINATION

         13.1 Term. This Agreement shall commence as of the Effective Date and,
unless sooner terminated as provided in this Article XIII, (a) the provisions
relating to Development and Commercialization shall continue in effect until the
Parties are not Developing or Commercializing any Collaboration Compounds or
Collaboration Products within the Royalty-Bearing Territory; and (b) the
provisions relating to Commercialization shall continue in effect until the date
on which Ortho is no longer obligated to pay a royalty to GTx on Royalty Bearing
Sales of Products or any Additional Royalty.

         13.2 Termination for Material Breach.

                  (a) Right to Terminate. Subject to the provisions of this
Section, if either Party (the "Breaching Party") shall have committed a Material
Breach and such Material Breach shall remain uncured and shall be continuing for
a period of one hundred twenty (120) calendar days following receipt of notice
thereof by the other Party (the "Non-Breaching Party"), then, in addition to any
and all other rights and remedies that may be available, the Non-Breaching Party
shall have the right to terminate this Agreement effective upon the expiration
of such one hundred twenty (120) calendar day period. Any such notice of alleged
Material Breach by one party (the "Accusing Party") shall include a reasonably
detailed description of all relevant facts and circumstances demonstrating,
supporting and/or relating to each such alleged Material Breach by the other
party ("Accused Breaching Party).

                  (b) Excuse. If the Accused Breaching Party, upon written
notice delivered to the Accusing Party prior to the expiration of such one
hundred twenty (120) calendar day period, shall assert in good faith that any
such alleged Material Breach described in the Accusing Party's notice, whether
in payment of moneys or otherwise, was not a Material Breach, or was excused by
reason of material failure of performance by the other Party or Third Parties or
by reason of Force Majeure, or shall otherwise in good faith dispute such
alleged Material Breach, then the Parties shall continue to perform under this
Agreement, subject to all of its terms and conditions, and the matter shall be
resolved pursuant to the provisions of Article XV. In such event, the Accusing
Party shall not be entitled to terminate this Agreement pursuant to this Section
unless and until (i) it shall be determined pursuant to Article XV that the
Accused Breaching Party has committed a Material Breach and (ii) such Material
Breach has not been cured prior to such determination pursuant to Article XV. To
the extent that it is determined pursuant to a final and non-appealable decision
under Article XV that the Accused Breaching Party did commit a Material Breach
and failed to cure the same within the period provided for in clause (ii) above,
then the Accusing Party may immediately terminate this Agreement and, in
addition to all damages determined pursuant to the provisions of Article XV to
be due and owing from the Breaching Party to the Non-Breaching Party under this
Agreement, the Breaching Party shall be liable for the Non-Breaching Party's
reasonable attorneys' fees incurred in connection with resolving such matter
pursuant to

                                       43



Article XV. If a final and non-appealable decision is made under Article XV that
no Material Breach was committed by the Accused Breaching Party, then the
decision maker under Article XV may elect to require the Accusing Party to pay
the Accused Breaching Party's attorneys' fees incurred in connection with
resolving such matter if he or she determines that the Accusing Party's basis
for providing a notice of Material Breach to the other Party was not reasonable.

                  (c) Termination. If the Non-Breaching Party terminates this
Agreement pursuant to the provisions of Sections 13.2(a) and (b), then the
following provisions shall apply:

                           (i) the Non-Breaching Party shall receive an
exclusive (even as to the Breaching Party), worldwide right and license, with
the right to grant sublicenses, to all Patents and Product-specific trademarks
Controlled by the Breaching Party as of the date of termination to the extent
that a license under such Patents and Trademarks is necessary to enable the
other Party to make, have made, import, export, use, sell, offer for sale and
have sold Collaboration Products without infringing such Patents or Trademarks.
The Non-Breaching Party shall also have the exclusive right (but not the
obligation), subject to the rights of Third Parties existing prior to the
Effective Date to enforce such Patents against competitive product infringement
relating to Collaboration Products, and the exclusive right (but not the
obligation) to enforce such Product-specific trademark rights against
infringers;

                           (ii) if Ortho is the Non-Breaching Party, pursuant to
Section 13.2(c)(i), the Co-Promotion shall cease and the royalty percentages
recited in Section 3.4 shall be offset by any damages incurred by the
Non-Breaching Party in connection with such Material Breach, provided that in no
event shall the royalty due pursuant to Section 3.4 be reduced by more than [ *
].

                           (iii) all licenses and rights to the Breaching Party
under the Non-Breaching Party's patents, trademarks, and know-how shall
terminate; and

                           (iv) all Confidential Information supplied by the
Non-Breaching Party to the Breaching Party shall be returned to the
Non-Breaching Party, except that the Breaching Party may retain one copy of such
information solely for legal archive purposes.

                  (d) Remaining Obligations. Except where expressly provided for
otherwise in this Agreement, termination of this Agreement shall not relieve the
Parties hereto of any liability, including any obligation to make payments
hereunder, which accrued hereunder prior to the effective date of such
termination, nor preclude any Party from pursuing all rights and remedies it may
have hereunder or at law or in equity with respect to any breach of this
Agreement nor prejudice any Party's right to obtain performance of any
obligation.

                  (e) "Material Breach". For purposes of this Agreement and
except as expressly provided otherwise in this Agreement, "Material Breach"
means the breach of

                                       44



or failure to perform, in a material respect, a Party's material obligations
under this Agreement. Without limiting the foregoing and by way of example only,
the term "Material Breach" shall be deemed to include [ * ]. In no event shall a
failure to [ * ], in and of itself, be deemed to constitute a Material Breach,
unless such failure is a result of acts, events or conduct that is otherwise a
Material Breach. The Parties acknowledge and agree that a failure to exercise
any right or option with respect to any Product shall not be deemed to
constitute a Material Breach hereunder.

                  (f) Survival. The provisions of this Section 13.2 shall
survive termination of this Agreement.

         13.3 Termination by Ortho. Ortho may terminate Development and/or
Commercialization of a Collaboration Compound and/or a Collaboration Product
upon [ * ] prior written notice to GTx; provided, however, that in the event
that termination is the result of a concern over Safety, termination shall be
effective [ * ] after written notice. Notwithstanding the foregoing, if Ortho
terminates the Agreement under this Section 13.3, and such termination is
effective prior to the completion of a clinical trial that has already begun,
Ortho shall be obligated to complete the clinical trial at its expense unless
the termination was for Safety-related reasons.

         13.4 Effect of Termination by GTx Under Section 13.2 or by Ortho
Pursuant to Section 13.3. If GTx terminates this Agreement for material breach
by Ortho pursuant to Section 13.2, or Ortho terminates this Agreement pursuant
to Section 13.3, Ortho shall continue to be obligated during the termination
notice period to perform all of its obligations under this Agreement, including
its obligation to pay Development Expenses; provided, however, that if such
termination occurred pursuant to Section 13.3, Ortho shall have no obligation to
make any milestone payments with respect to any milestone achieved during the
termination notice period. In addition, as a result of any such termination:

                  (a) all licenses and rights to GTx Patents and GTx Know-how
granted to Ortho hereunder shall terminate;

                  (b) all Confidential Information supplied by GTx to Ortho
shall be returned to GTx, except that Ortho may retain one copy of such
information solely for legal archive purposes;

                  (c) Ortho shall be obligated to GTx under Section 8.5 to the
extent provided therein, except wherein termination is under Section 13.3 as the
result of a Safety issue;

                  (d) Ortho shall promptly transfer and assign ownership of all
INDs, Drug Approval Applications and Regulatory Approvals related to
Collaboration Compounds, Collaboration Products to GTx, and shall take such
other actions and execute such other instruments, assignments and documents as
may be necessary to effect the transfer of rights hereunder to GTx; and

                                       45



                  (e) Ortho shall grant GTx (i) an exclusive, royalty-free,
worldwide license to all Joint Patents to make, use, sell, offer for sale and
import Collaboration Products, (ii) an exclusive, worldwide royalty-bearing
license under Ortho Patents covering Inventions to make use, sell, offer for
sale and import Collaboration Products, and (iii) an exclusive, royalty-free,
worldwide license under all trademarks Controlled by Ortho that are used, or
intended for use, specifically with Collaboration Products. GTx shall have the
right to grant sublicenses under the foregoing licenses. If such termination
occurs after completion of a Phase IIB Clinical Trial for a Collaboration
Product (determined by the completion of the final report for the study), GTx
shall pay to Ortho a royalty on Collaboration Products covered by a Valid Claim
of an Ortho Patent equal to [ * ] of Net Sales of such Collaboration Products
(calculated as if such sales were by Ortho) provided that the offsets and
reductions set forth in Sections 3.5 and 3.6 shall apply mutatis mutandis to the
calculation of the royalty due to Ortho pursuant to this Section 13.4.
Additionally, in any termination by GTx pursuant to Section 13.2 or by Ortho
pursuant to Section 13.3, GTx shall have the exclusive right (but not the
obligation) to enforce such Patents against competitive product infringement
relating to Collaboration Products, and such trademarks against infringers.

         13.5 Surviving Rights. The rights and obligations set forth in this
Agreement shall extend beyond the term or termination of the Agreement only to
the extent expressly provided for herein, or the extent that the survival of
such rights or obligations are necessary to permit their complete fulfillment or
discharge. Without limiting the foregoing, Sections 3.7, 8.5, 10.1, 12.2 and
12.3 (as to activities occurring during the term of the Agreement), 12.4, 13.4
(if applicable to such termination), and 13.5, and Articles 14 (as applicable to
activities conducted during the term of the Agreement or pursuant to licenses
retained by a party thereafter, and as to Section 14.4, as provided therein), 15
and 16 shall survive expiration or termination of this Agreement.

         13.6 Change of Control. In the event of a GTx Change of Control
(defined below), Ortho shall have the following rights and options with respect
to this Agreement:

                  (a) Notice by Ortho. In the event that a GTx Change of Control
occurs during the term of this Agreement, Ortho shall have the right and option,
exercisable upon written notice to GTx delivered at any time within sixty (60)
calendar days after the effective date of such Change of Control, to terminate
GTx's right of Co-Promotion.

                  (b) Royalty Payment Upon Termination by Ortho of Co-Promotion.
Upon a Change of Control, if Ortho elects to terminate GTx's rights of
Co-Promotion pursuant to Section 13.6(a), then Ortho shall pay to GTx (or its
successor, if not GTx) a Royalty Payment under this Section 13.6(b) on Net Sales
of Collaboration Products by Ortho, its Affiliates or sublicensees in the United
States to Urologists, to compensate GTx for the Additional Royalty that GTx
would have had the opportunity to earn had Co-Promotion not terminated, as
follows:

                           (i) Termination If GTx has Co-Promoted [ * ]. If at
the time Ortho terminates Co-Promotion, GTx has been Co-Promoting at least one
(1)

                                       46



Collaboration Product for [ * ], then Ortho would pay to GTx for each
Collaboration Product that has then been Co-Promoted by GTx for [ * ] a Royalty
Payment B, calculated as follows:

                           [ * ]

                                            [ * ]

Ortho would pay to GTx all Royalty Payments due to it pursuant to this Section
13.6(b)(i) from the date that GTx's Co-Promotion right terminates [ * ].

                           (ii) Termination If GTx Has [ * ]. If at the time
Ortho terminates GTx's right of Co-Promotion, [ * ], or GTx has been
Co-Promoting a Collaboration Product to the GTx Audience for [ * ], then Ortho
would pay to GTx a Royalty Payment B2 calculated as follows:

                           [ * ]

                                    [ * ]

Ortho would pay to GTx such Royalty Payment for each such Collaboration Product
from either (i) the Marketing Date for such Product, if such date had not
occurred when GTx's right of Co-Promotion terminated, or (ii) the date of
termination of GTx's right of Co-Promotion, if the Marketing Date had occurred
prior thereto (either (i) or (ii), as applicable, the "Start Date"), [ * ].

                           EXAMPLE 1 (Section 13.6(b)(i) Scenario):

                           [ * ]

                           EXAMPLE 2 (Section 13.6(b)(i) Scenario):

                           [ * ]

                           EXAMPLE 3 (Section 13.6(b)(ii) Scenario):

                           [ * ]

                           (iii) Payments. The foregoing Royalty Payment for the
relevant calendar quarter would be paid at the times and in the manner set forth
in Article III for royalties due to GTx. Additional Royalties due pursuant to
this Section 13.6 shall not be subject to any offsets or reductions that may be
applicable to royalties due to GTx pursuant to Section 3.4. GTx shall have the
right to audit Ortho's records to confirm the accuracy of payments made
hereunder as provided in Section 12.4.

                           (iv) Limitation; Clarification. For clarity, if at
the time GTx's right of Co-Promotion terminates, GTx is [ * ] that is later [ *
], then a Royalty Payment would be due to GTx with respect to [ * ].

                                       47



                  (c) Definitions. For the purposes of this Section 13.6, the
following terms shall have the following definitions:

                           (i) "GTx Change of Control" means any transaction or
series of related transactions in which a Major Health Care Company acquires or
becomes the beneficial owner of (i) more than [ * ] of the outstanding voting
securities of GTx or the surviving entity, whether by merger, consolidation,
reorganization, tender offer or similar means, or (ii) all or substantially all
of the assets of GTx.

                           (ii) "Major Health Care Company" shall mean a Third
Party pharmaceutical or biotechnology company (including a "group" within the
meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 but excluding
Ortho and any affiliates of Ortho) whose worldwide net sales of human
pharmaceutical products, including consumer over-the-counter pharmaceutical
products, in the most recently completed fiscal year for which audited financial
statements are publicly available at the time such Change of Control occurs,
causes such company (or group) [ * ], or if such information is not publicly
available, as appropriately provided by GTx.

                                  ARTICLE XIV

                                 INDEMNIFICATION

         14.1 Ortho and GTx. Ortho and GTx shall each indemnify, defend and hold
harmless the other Party and their officers, directors, agents, employees and
Affiliates against and from any and all Third Party actions, proceedings,
claims, suits, judgments, expenses (including reasonable attorney fees), losses,
liabilities and damages (collectively, "Indemnification Claims" or "Claims")
which the other Party may incur or suffer to the extent such arise out of or are
based upon (i) the material default by such Party in the performance of any
obligation of a Party in this Agreement or the material breach of any warranty,
representation, or agreement made by such Party in this Agreement, (ii) the
intentional misconduct or negligent acts or omissions to act, (iii) any
noncompliance by such Party of applicable laws, rules or regulations in the
course of its conduct under this Agreement.

         14.2 Ortho. Ortho further agrees to defend, indemnify and hold harmless
GTx, its officers, directors, agents, employees and Affiliates, from and against
(i) all Claims incurred by or assessed against GTx for activities prior to any
termination of this Agreement on account of any claim that the manufacture, use
or sale of Collaboration Product in the Territory infringes the patent,
trademark or other intellectual property right of any third party, or (ii) any
Claims relating to personal injuries (including death) or product liability or
other loss or damage by Third Parties resulting from or relating to the
manufacture, labeling, sale, use, storage, transportation, distribution or
handling of Collaboration Product, unless and to the extent such loss or damage
was primarily due to the negligence, recklessness or willful misconduct of GTx
(whether committed by affirmative act or by omission).

                                       48



         14.3 Procedure. The Party seeking indemnification (the "Indemnified
Party") shall inform the other Party promptly of any such Indemnifiable Claim
which is brought against it and shall, to the extent such Indemnifiable Claim is
brought by a Third Party, at the other Party's request, cooperate fully with the
other Party in defending such Indemnifiable Claim. The Indemnified Party, at its
expense, shall have the right to advise and consult on and participate in any
related suit or proceeding, subject to the ultimate control of the Indemnifying
Party. The other Party ("Indemnifying Party") shall have full control over the
suit or proceedings, including the right to settle, through counsel of its
choice who is reasonably acceptable to the Indemnified Party; provided, however,
the Indemnifying Party will not, absent the consent of the Indemnified Party
(which consent will not be unreasonably withheld), consent to the entry of any
judgment or enter into any settlement that (1) provides for any relief other
than the payment of monetary damages for which the Indemnifying Party shall be
solely liable and (2) where the claimant or plaintiff does not release the
Indemnified Party from all liability in respect thereof. If the Indemnifying
Party declines to accept control of the defense of such claim or action, the
Indemnified Party may retain counsel at the expense of the Indemnifying Party
and control the defense of the claim or action, provided that the claim or
action may not be settled by the Indemnified Party without the approval of the
Indemnifying Party, which approval shall not be unreasonably withheld or
delayed. Any payment made by the Indemnifying Party to settle any claim or
action hereunder shall be at its own cost and expense.

         14.4 Insurance. GTx agrees during the term of the Agreement and for a
period of at least three (3) years thereafter to maintain (a) workers'
compensation insurance for all of its employees, the limits of which shall be as
required under statute; and (b) commercial general liability insurance
(including but not limited to product liability insurance, including for
clinical trials and contractual liability coverage) on a claims made form having
limits of not less than [ * ] and [ * ]. When GTx hires sales representatives
(if it exercises its right to Co-Promote), it shall expand its coverage to
include automobile insurance, and it shall increase its commercial general
liability insurance and product liability insurance to have limits of not less
than [ * ] and [ * ]. For all insurance coverage written on a claims made basis,
the retroactive date, if any, shall precede the Effective Date. In addition, GTx
shall [ * ] if the policy or policies are cancelled or not renewed and not
replaced by another claims made policy with the same (or an earlier) retroactive
date either [ * ]. All insurance companies must be rated A or better in the most
recent AM Best Rating Guide. GTx, upon request, agrees to provide Ortho with a
certificate of insurance evidencing its retention of such insurance coverage and
any updates thereto.

                                   ARTICLE XV

                               DISPUTE RESOLUTION

         15.1 Disputes. The Parties recognize that disputes as to certain
matters may from time to time arise during the term of this Agreement that
relate to either Party's rights and/or obligations hereunder. It is the
objective of the Parties to establish procedures to facilitate the resolution of
disputes arising under this Agreement in an

                                       49



expedient manner by mutual cooperation and without resort to litigation. To
accomplish this objective, the Parties agree to follow the procedures set forth
in this if and when a dispute arises under this Agreement.

         15.2 Disputes Referred First to Executive Officers. Unless otherwise
specifically recited in this Agreement, disputes between the Parties shall be
referred to the Parties' respective Executive Officers or their successors, for
attempted resolution by negotiations [ * ] after such issue is submitted for
resolution to such officers.

         15.3 Resolution of Dispute by Alternate Means. In the event the
designated Executive Officers are not able to resolve such dispute, either Party
may at any time after the [ * ] period seek to resolve the dispute through other
means as provided herein; provided, however, disputes regarding strategies for
Development or the content of the Development Plan or Development Budget and
those that arise with respect to marketing strategies or the content of the
Marketing and Sales Plan shall be resolved in favor of Ortho (to the extent
consistent with this Agreement) and not subject to the Alternative Dispute
Resolution provided in this Article XV.

         15.4 Alternative Dispute Resolution. Any dispute controversy or claim
arising out of or relating to the validity, construction, enforceability or
performance of this Agreement, including disputes relating to an alleged breach
or to termination of this Agreement, but excluding (i) any dispute, controversy
or claim arising out of or relating to the validity, enforceability, or
infringement of any GTx Patent or any Ortho Patent and (ii) other than disputes
which are expressly prohibited herein from being resolved by this mechanism,
shall be settled by binding Alternative Dispute Resolution ("DR") in the manner
described below:

                  (a) If a Party intends to begin a DR to resolve a dispute,
such Party shall provide written notice (the "DR Request") to counsel for the
other Party informing such other Party of such intention and the issues to be
resolved.

                  (b) [ * ] after receipt of the DR Request, the other Party
may, by written notice to counsel for the Party initiating DR, add additional
issues to be resolved.

         15.5 Arbitration Procedures. A DR initiated under this Agreement will
proceed in accordance with the Commercial Arbitration Rules of the American
Arbitration Association for Large, Complex Cases then in effect, insofar as such
rules are not inconsistent with the provisions expressly set forth in this
Agreement, unless the Parties mutually agree otherwise. However, the Parties do
not intend to submit the issue for resolution by such association unless they
mutually agree to do so, in writing.

         15.6 Arbitrators. The arbitration shall be carried out by a single
arbitrator who shall be a retired United States judge or justice and shall be
selected by the Parties [ * ] of receipt of the DR Request in accordance with
the procedure described below:

                  (a) The Parties shall select the arbitrator as described
below, which may but need not be selected from a list of arbitrators such as the
CPR Panel of Distinguished Neutrals of the Center for Public Resources, subject
to: (1) his/her

                                       50



availability and willingness to serve, (2) his/her availability to commence the
arbitration within a reasonable period of time, (3) his/her agreement to charge
fees and expenses that are reasonable under the circumstances, and (4) his/her
commitment to render his/her award within the time periods provided in this
Section.

                  (b) Each Party will exchange a list of [ * ] qualified
arbitrators and in the event that both Parties agree on a single person then
such person shall be the arbitrator. In submitting the ten names, each Party
shall prioritize from one to ten the persons on their respective lists. In the
event that there is more than one common name on the Parties' lists, the person
having the lowest combined priority number shall be selected as the arbitrator.
The combined priority number shall be the sum of the order numbers assigned to
that person by the Parties. Thus, if one person was GTx's number two priority
and Ortho's number three priority, and another person was GTx's number two
priority and Ortho's number four priority, the former would be appointed. If
more than one person has the lowest combined priority number, the person for
whom there is less difference between the order numbers assigned by the Parties
shall be appointed. Thus, if one person was GTx's number one priority and
Ortho's number four priority, and another person was GTx's number two priority
and Ortho's number three priority, the latter person would be appointed. If this
method does not produce an arbitrator, or if there are no common names, the
Parties shall alternatively strike from the combined list until only one name
remains, which shall be selected as the arbitrator. The Party to strike first
shall be determined by the toss of a coin.

                  (c) In the event the arbitrator is unable to meet the
requirements set forth in (a) above, then, in the event the first selected
arbitrator was common to both lists and there was more than one common name on
the Parties' lists, the arbitrator having the next lowest combined priority
number who is able and willing to serve pursuant to these requirements shall be
selected. If there is no such individual, then the Parties shall use the
alternate strike method set forth above. In the event an arbitrator selected by
the alternate strike methodology is unable or unwilling to serve consistent with
the requirements set forth above, then the alternate striking procedure shall be
retraced in reverse order until the arbitrator is selected.

                  (d) The arbitrator shall be neutral, disinterested, impartial,
and independent of the Parties and others having any known interest in the
outcome, and shall abide by the AAA/ABA Code of Ethics for Arbitrators in
Commercial Disputes. There shall be no ex parte communications with the
arbitrator either before or during the arbitration, relating to the dispute or
issues involved in the dispute or the arbitrator's views on any such issue.

         15.7 Interim Review. Either Party may apply to any court having
jurisdiction hereof and seek preliminary injunctive relief until such time as
the arbitration award is rendered or the controversy is otherwise resolved.

         15.8 Location. Any arbitration under this Section shall be conducted in
New York, NY.

                                       51



         15.9 Discovery Proceedings. The Parties shall have the right to
undertake complete discovery, as contemplated by and pursuant to Federal Rules
26-37 of the Federal Rules of Civil Procedure (with references to "court" in
those Rules being considered references to the "arbitrator") except as they may
be modified by the following:

                  (a) [ * ] after selection of the arbitrator, each Party may
serve on any other Party (i) interrogatories for the purpose of identification
of documents and witnesses, (ii) requests for admissions, and (iii) requests for
the production of documents and things. These discovery requests will be
answered [ * ] of receipt.

                  (b) At any time but not more than [ * ] after the selection of
the arbitrator, each Party may take depositions of employees or other witnesses
of an opposing Party as a matter of right, subject to applicable limitations set
forth in Rules 26-37.

                  (c) Any Party may conduct depositions of its own witnesses
which may be introduced as evidence at the arbitration hearing if the other
Party was given fair opportunity to attend the deposition and cross-examine.

                  (d) As they become aware of new documents or information,
including experts who may be called upon to testify, all Parties remain under a
continuing obligation to provide documents upon which they rely, to supplement
their responses, and to honor any informal agreements or understandings between
the Parties regarding documents or information to be exchanged. The arbitrator
at the hearing will not consider documents that have not been previously
exchanged, unless agreed by the Parties or used for purposes of impeachment.

                  (e) The Parties will promptly notify the arbitrator when an
unresolved dispute exists regarding discovery issues. The arbitrator will
discuss the matter with the Parties to determine the nature of the dispute and
will attempt to resolve that dispute. If the arbitrator does not resolve the
dispute, the arbitrators will arrange a conference concerning the dispute before
the arbitrator by telephone, or in person, and the arbitrator will decide the
dispute.

                  (f) All discovery shall be completed [ * ] from selection of
the arbitrator, unless extended by agreement of the Parties or by the arbitrator
for good cause shown.

         15.10 Hearings and Proceedings. The arbitrator will determine the
specific location within New York, NY and the date and time of the arbitration
hearing(s) and other proceedings after consultation with the arbitrator and the
Parties and will provide reasonable notice of the hearing(s) date and time. The
arbitrator will make every effort to schedule the arbitration hearing [ * ] of
the completion of all discovery, absent unusual circumstances.

                  (a) The Parties may mutually agree on or the arbitrator for
good cause may order a rescheduling of the hearing date.

                                       52



                  (b) The arbitrator will ordinarily conduct the arbitration
hearing in the manner set forth in this Section except that (i) the Federal
Rules of Evidence shall apply and (ii) the arbitrator shall render its decision
in writing in the manner provided by Rule 52 of the Federal Rules of Civil
Procedure, including a full and precise statement of the factual and legal bases
for such decision. If the AAA rules and the rules of this Section conflict in
any manner, the rules of this Section shall prevail. The arbitrator must hold an
oral hearing, but may impose reasonable time limits on each phase of the
proceeding and may limit testimony to exclude evidence that would be immaterial
or unduly repetitive, provided that all Parties are afforded the opportunity to
present material and relevant evidence and that each Party is given at least an
approximately equal amount of time for presentation of its case.

                  (c) Written briefs may be filed up to [ * ] before the
hearing.

                  (d) The arbitrator will require witnesses to testify under
oath if requested by any Party.

                  (e) Any Party desiring a stenographic record may secure a
court reporter to attend the proceedings.

                  (f) The arbitrator will determine the order of proof, which
will generally be similar to that of a court trial, including opening and
closing statements.

                  (g) When the arbitrator determines that all relevant and
material evidence and arguments have been presented, the arbitrator will declare
the hearing closed. The arbitrator may defer the closing of the hearing for up
to [ * ] to permit the Parties to submit post-hearing briefs and or to make
closing arguments, as the arbitrator deems appropriate, before rendering an
award.

                  (h) The arbitrator will render the award and its decisions
pursuant to Fed. R. Civ. P. 52 [ * ] after the date of the closing of the
hearing or, if an arbitration hearing has been waived, [ * ] after the date of
the arbitrator's receiving all materials specified by the Parties. The decision
and award of the arbitrator will constitute the Arbitration Award and will be
binding on the Parties.

                  (i) The arbitrator shall, in rendering his or her decision and
award, apply the substantive law of the State of New York, without regard to its
conflict of laws provisions, except that the interpretation of and enforcement
of this Article shall be governed by the Federal Arbitration Act. The costs of
the winning Party and the fees of the arbitrator shall be paid by the losing
Party as determined by the arbitrator. If the arbitrator is unable to designate
a losing party, it shall so state and each Party shall bear its own costs and
the fees of the arbitrator shall be split equally between the Parties.

         15.11 Award. The arbitrator is empowered to award any remedy allowed by
law, including money damages, prejudgment interest and attorneys' fees, and to
grant final, complete, interim, or interlocutory relief, including injunctive
relief. Notwithstanding the foregoing, punitive or multiple damages may not be
awarded.

                                       53



         15.12 Legal Fees. Except as set forth in Section 15.10(i) above, each
Party shall bear its own legal fees.

         15.13 Confidentiality. The DR proceeding shall be confidential and the
arbitrator shall issue appropriate protective orders to safeguard each Party's
Confidential Information. Except as required by law, no Party shall make (or
instruct the arbitrator to make) any public announcement with respect to the
proceedings or decision of the arbitrator without prior written consent of each
other Party. The existence of any dispute submitted to DR, and the award, shall
be kept in confidence by the Parties and the arbitrator, except as required in
connection with the enforcement of such award or as otherwise required by
applicable law.

         15.14 Survivability. Any duty to arbitrate under this Agreement shall
remain in effect and enforceable after termination of this Agreement for any
reason.

         15.15 Jurisdiction. For the purposes of this Article each Party agrees
to abide by the award rendered in any arbitration, and the Parties agree to
accept the jurisdiction of any court having jurisdiction over the Parties for
the purposes of enforcing awards entered pursuant to this Article and for
enforcing the agreements reflected in this Article, provided that the foregoing
shall not be deemed to waive any rights of either Party under the Federal
Arbitration Act.

                                  ARTICLE XVI

                                  MISCELLANEOUS

         16.1 Assignment.

                  (a) Affiliates. Either Party may assign any of its rights or
obligations under this Agreement in any country to its Affiliates and may
delegate its obligations under this Agreement in any country to its Affiliates;
provided, however, that such assignment or delegation shall not relieve the
assigning Party of its responsibilities for performance of its obligations under
this Agreement.

                  (b) (i) Non-Affiliates. Except as provided in subsection
(b)(ii) below, neither Party may assign its rights or obligations under this
Agreement to a non-Affiliate without the prior written consent of the other
Party, except in connection with a merger or similar reorganization or the sale
of all or substantially all of its assets. This Agreement shall survive any such
merger or reorganization of either Party with or into, or such sale of assets
to, another party and no consent for such merger, reorganization or sale shall
be needed; provided, that in the event of such merger, reorganization or sale,
no intellectual property rights of the acquiring corporation shall be included
in the technology licensed hereunder.

                      (ii) GTx's Right to Assign Rights to Receive Payment.
GTx may assign its rights to receive payments hereunder to a Third Party or
grant a security interest in its rights to receive payments hereunder.

                                       54



                  (c) Benefit to Successors. This Agreement shall be binding
upon and inure to the benefit of the successors and permitted assigns of the
Parties. Any assignment not in accordance with this Agreement shall be void.

         16.2 Retained Rights. Nothing in this Agreement shall limit in any
respect the right of either Party to conduct research and development and to
market products using such Party's technology other than as herein expressly
provided.

         16.3 Consents Not Unreasonably Withheld or Delayed. Whenever provision
is made in this Agreement for either Party to secure the consent or approval of
the other, that consent or approval shall not unreasonably be withheld or
delayed, and whenever in this Agreement provision is made for one Party to
object to or disapprove a matter, such objection or disapproval shall not
unreasonably be exercised, even when not so expressly stated.

         16.4 Force Majeure. Neither Party shall lose any rights hereunder or be
liable to the other Party for damages or losses on account of failure of
performance by the defaulting Party if the failure is occasioned by government
action, war, fire, explosion, flood, strike, lockout, embargo, act of God, or
any other similar cause beyond the control of the defaulting Party, provided
that the Party claiming force majeure has exerted all reasonable efforts to
avoid or remedy such force majeure and has given the other Party prompt notice
describing such event, the effect thereof and the actions being taken to avoid
or remedy such force majeure; provided, however, that in no event shall a Party
be required to settle any labor dispute or disturbance.

         16.5 Further Actions. Each Party agrees to execute, acknowledge and
deliver such further instruments, and to do all such other acts, as may be
necessary or appropriate in order to carry out the purposes and intent of this
Agreement.

         16.6 No Trademark Rights. Except as otherwise provided herein, no
right, express or implied, is granted by the Agreement to use in any manner any
name or any trade name or trademark of the other Party or its Affiliates in
connection with the performance of this Agreement.

         16.7 Notices. All notices hereunder shall be in writing and shall be
deemed given if delivered personally or by facsimile transmission (receipt
verified), telexed, mailed by registered or certified mail (return receipt
requested), postage prepaid, or sent by express courier service, to the Parties
at the following addresses (or at such other address for a Party as shall be
specified by like notice; provided that notices of a change of address shall be
effective only upon receipt thereof).

                                       55



         If to GTx:             GTx, Inc.
                                3 North Dunlap St.
                                3rd Floor
                                Memphis, Tennessee 38163
                                U.S.A.
                                Attention:  President
                                Facsimile No.:  [ * ]

         With a copy to:        GTx, Inc.
                                3 North Dunlap St.
                                3rd Floor
                                Memphis, Tennessee 38163
                                U.S.A.
                                Attention:  General Counsel
                                Facsimile No.: [ * ]

         If to Ortho:           Ortho Biotech Products, L.P.
                                Route 22 East
                                Bridgewater, NJ 08807
                                U.S.A.
                                Attention:  President
                                Facsimile No.:  [ * ]

         16.8 Waiver. Except as specifically provided for herein, the waiver
from time to time by either of the Parties of any of their rights or their
failure to exercise any remedy shall not operate or be construed as a continuing
waiver of same or any other of such Party's rights or remedies provided in this
Agreement.

         16.9 Severability. If any term, covenant or condition of this Agreement
or the application thereof to any Party or circumstances shall, to any extent or
in any country, be held to be invalid or unenforceable, then (i) the remainder
of this Agreement, or the application of such term, covenant or condition to
Parties or circumstances other than those as to which it is held invalid or
unenforceable, shall not be affected thereby and each term, covenant or
condition of this Agreement shall be valid and be enforced to the fullest extent
permitted by law; and (ii) the Parties hereto covenant and agree to renegotiate
any such term, covenant or application thereof in good faith in order to provide
a reasonably acceptable alternative to the term, covenant or condition of this
Agreement or the application thereof that is invalid or unenforceable, it being
the intent of the Parties that the basic purposes of this Agreement are to be
effectuated.

         16.10 Ambiguities. Ambiguities, if any, in this Agreement shall not be
construed against any Party, irrespective of which Party may be deemed to have
authored the ambiguous provision.

         16.11 Governing Law. This Agreement shall be governed by and
interpreted under the laws of the State of New Jersey as applied to contracts
entered into and performed entirely in New Jersey by New Jersey residents.

                                       56



         16.12 Headings. The Sections and paragraph headings contained herein
are for the purposes of convenience only and are not intended to define or limit
the contents of said Sections or paragraphs.

         16.13 Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

         16.14 Entire Agreement; Amendments. This Agreement, including all
Exhibits attached hereto, and all documents delivered concurrently herewith, set
forth all the covenants, promises, agreements, warranties, representations,
conditions and understandings between the Parties hereto and supersede and
terminate all prior agreements and understandings between the Parties. There are
no covenants, promises, agreements, warranties, representations, conditions or
understandings, either oral or written, between the Parties other than as set
forth herein. No subsequent alteration, amendment, change or addition to this
Agreement shall be binding upon the Parties hereto unless reduced to writing and
signed by the respective authorized officers of the Parties. This Agreement,
including without limitation the exhibits, schedules and attachments hereto, are
intended to define the full extent of the legally enforceable undertakings of
the Parties hereto, and no promise or representation, written or oral, which is
not set forth explicitly is intended by either party to be legally binding.

Both Parties acknowledge that in deciding to enter into the Agreement and to
consummate the transaction contemplated thereby neither Party has relied upon
any statement or representations, written or oral, other than those explicitly
set forth herein.

         16.15 Independent Contractors. The status of the Parties under this
Agreement shall be that of independent contractors. Neither Party shall have the
right to enter into any agreements on behalf of the other Party, nor shall it
represent to any person that it has any such right or authority. Nothing in this
Agreement shall be construed as establishing a partnership or joint venture
relationship between the Parties.

         16.16 Currency Exchange. All payments to be made by Ortho to GTx shall
be made in U.S. Dollars, to a GTx bank account able to receive U.S. Dollars.
Payments by Ortho to GTx shall be converted to U.S. Dollars in accordance with
the following: the rate of currency conversion shall be calculated using a
simple average of the mid-month and month-end rates as provided by Brown
Brothers Harriman, 59 Wall Street, NY, NY 10005, for each relevant period, or if
such rate is not available, the spot rate as published by The Wall Street
Journal, Eastern Edition for such accounting period. This method of conversion
is and shall be consistent with Ortho's then current methods, provided that such
method shall utilize Third Party indices that are publicly available. Ortho
shall give GTx prompt written notice of any changes to Ortho's customary and
usual procedures for currency conversion, which shall only apply after such
notice has been delivered and provided that such changes continue to maintain a
set methodology for currency conversion.

                                       57



         IN WITNESS WHEREOF, GTx and Ortho have caused this Agreement to be
executed as of the Effective Date first written above by their respective
officers thereunto duly authorized.

         GTX, INC.

         Signed By: /s/ Mitchell S. Steiner, M.D.
                    ----------------------------------
         Title:     CEO / Vice Chairman

         ORTHO BIOTECH PRODUCTS L.P.

         Signed By: /s/ J. H. Johnson
                    ----------------------------------
         Title:     President

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       58



Exhibits

         Exhibit A - List of GTx Patents

         Exhibit B - Adverse Event Reporting Procedures

         Exhibit C - Initial Plan

         Exhibit D1 - Compounds that Fall Within Section 1.36(1)

         Exhibit D2 - Excluded SARM Compounds

                                       59



                                   EXHIBIT A



U.S. PATENT APPLICATION OR
        PATENT NO.             FILING DATE         STATUS          ISSUE DATE       ASSIGNEES
- ---------------------------- ----------------- ---------------- ----------------- -----------------
                                                                      
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------
           [ * ]                  [ * ]            [ * ]             [ * ]
- ---------------------------------------------------------------------------------------------------


[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       60



EXHIBIT B

                       ADVERSE EVENT REPORTING PROCEDURES

There will be one common database for both clinical and post-marketing adverse
event data, which shall be the responsibility of Ortho. Ortho shall be
responsible for furnishing timely notice of adverse events, including drug
interactions, as required by applicable regulations, to all competent
governmental agencies with respect to the Collaboration Products. GTx shall
provide Ortho with all necessary assistance in complying with all adverse event
reporting requirements established by, or required under, any applicable IND,
NDA or Regulatory Approval and/or applicable law.

GTx shall furnish Ortho with timely notice of adverse events relating to
Andarine or Collaboration Product(s), that it becomes aware of within the U.S.
Ortho shall perform active follow-up to obtain adequate details of reports
received to allow evaluation of reports of adverse events and drug interactions.
Each party shall retain all documents, reports, studies and other materials
relating to any and all adverse events.

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       61



EXHIBIT C

                                  INITIAL PLAN

                                      [* ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       62




EXHIBIT D1

                   COMPOUNDS THAT FALL WITHIN SECTION 1.36(1)

                                      [ * ]

[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       63



EXHIBIT D2 - EXCLUDED SARM COMPOUNDS



TYPE OF SARM
 COMPOUNDS                                 EXCLUDED SARM COMPOUNDS
- ------------------    -------------------  -----------------------
                                     
[ * ]                                            [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]

- ------------------    -------------------  -----------------------
[ * ]                                            [ * ]

                                                 [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]

- ------------------    -------------------  -----------------------
[ * ]                                            [ * ]
                                                 [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
- ------------------    -------------------  -----------------------
[ * ]                                            [ * ]
                                                 [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
                                                      [ * ]
- ------------------    -------------------  -----------------------


[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                       64



                                TABLE OF CONTENTS



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
ARTICLE I             DEFINITIONS.................................................................      1

         1.1      "Active Ingredient".............................................................      1

         1.2      "Additional Collaboration Compound".............................................      1

         1.3      "Affiliate".....................................................................      1

         1.4      "Andarine"......................................................................      2

         1.5      "Business Day" .................................................................      2

         1.6      "Clinical Studies"..............................................................      2

         1.7      "Collaboration Compound"........................................................      2

         1.8      "Collaboration Product".........................................................      2

         1.9      "Combination Product"...........................................................      2

         1.10     "Commercialization Activities"..................................................      2

         1.11     "Confidential Information"......................................................      2

         1.12     "Control" or "Controlled".......................................................      2

         1.13     "Co-Promotion"..................................................................      2

         1.14     "Co-Promotion Territory"........................................................      3

         1.15     "Detail"........................................................................      3

         1.16     "Development" or "Develop"......................................................      3

         1.17     "Development Budget"............................................................      3

         1.18     "Development Expenses"..........................................................      3

         1.19     "Development Plan"..............................................................      4

         1.20     "Drug Approval Application".....................................................      4

         1.21     "Education".....................................................................      4

         1.22     "Effective Date"................................................................      4

         1.23     "EMEA"..........................................................................      4

         1.24     "Executive Officers"............................................................      4

         1.25     "FDA"...........................................................................      4

         1.26     "First Collaboration Compound"..................................................      4

         1.27     "[ * ]".........................................................................      4

         1.28     "FTE"...........................................................................      4

         1.29     "FTE Cost"......................................................................      5

         1.30     "FTE Rate"......................................................................      5

         1.31     "Generic".......................................................................      5


                                      -i-




                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         1.32     "GTx Audience"..................................................................      5

         1.33     "GTx Know-how"..................................................................      5

         1.34     "GTx/Ortho Development".........................................................      5

         1.35     "GTx Patent"....................................................................      5

         1.36     "GTx SARM Compounds"............................................................      5

         1.37     "IND"...........................................................................      6

         1.38     "Indication"....................................................................      6

         1.39     "Information"...................................................................      6

         1.40     "Joint Development Committee" or "JDC"..........................................      7

         1.41     "Joint Patent"..................................................................      7

         1.42     "Koseisho"......................................................................      7

         1.43     "Launch Date"...................................................................      7

         1.44     "Major European Country"........................................................      7

         1.45     "Market Exclusivity"............................................................      7

         1.46     "Marketing".....................................................................      7

         1.47     "Marketing Expenses"............................................................      7

         1.48     "Marketing and Sales Committee".................................................      7

         1.49     "Marketing and Sales Plan"......................................................      7

         1.50     "Material Breach"...............................................................      7

         1.51     "NDA"...........................................................................      7

         1.52     "NDA Approval"..................................................................      7

         1.53     "Net Sales".....................................................................      7

         1.54     "Ortho Development".............................................................      9

         1.55     "Ortho Know-how"................................................................      9

         1.56     "Ortho Patent"..................................................................      9

         1.57     "Osteoporosis Indication".......................................................      9

         1.58     "[ * ]".........................................................................      9

         1.59     "Patent"........................................................................     10

         1.60     "Patent Expenses"...............................................................     10

         1.61     "Phase I Clinical Trial"........................................................     10


                                      -ii-



                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         1.62     "Phase IIA Clinical Trial"......................................................     10

         1.63     "Phase IIB Clinical Trial"......................................................     10

         1.64     "Phase III Clinical Trials".....................................................     10

         1.65     "Phase IIIB Clinical Trials"....................................................     10

         1.66     "Phase IV Clinical Trials"......................................................     10

         1.67     "Pre-Clinical Studies"..........................................................     11

         1.68     "Pre-Marketing".................................................................     11

         1.69     "Products"......................................................................     11

         1.70     "Proof of Concept Trial"........................................................     11

         1.71     "Regulatory Agency".............................................................     11

         1.72     "Regulatory Approval"...........................................................     11

         1.73     "Replacement Collaboration Compound"............................................     11

         1.74     "Royalty Bearing Product".......................................................     11

         1.75     "Royalty Bearing Sales".........................................................     11

         1.76     "Royalty Bearing Territory".....................................................     11

         1.77     "Royalty Term"..................................................................     11

         1.78     "Safety"........................................................................     12

         1.79     "[ * ]".........................................................................     12

         1.80     "Third Party"...................................................................     12

         1.81     "Tolerability"..................................................................     12

         1.82     "Trademark Expenses"............................................................     12

         1.83     "Unit Net Sales Price"..........................................................     12

         1.84     "Urologist".....................................................................     12

         1.85     "UTRF"..........................................................................     12

         1.86     "Valid Patent Claim"............................................................     12

         1.87     "Wasting Indication"............................................................     12

ARTICLE II            MANAGEMENT..................................................................     13

         2.1      Joint Development Committee.....................................................     13

ARTICLE III           LICENSING FEES; MILESTONE PAYMENTS; ROYALTIES; REPORTING....................     14


                                     -iii-




                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         3.1      Licensing Fee...................................................................     14

         3.2      Milestone Payments..............................................................     14

         3.3      Limitation on Milestone Payments................................................     17

         3.4      Royalty Rates...................................................................     18

         3.5      Payment of Royalties............................................................     18

         3.6      Payment of Third Party Royalties................................................     20

         3.7      Ortho's Rights Upon Expiration of Royalty Term..................................     20

         3.8      Compulsory License..............................................................     20

         3.9      Sales by Sublicensees...........................................................     20

         3.10     Tax Matters.....................................................................     20

         3.11     United States Dollars...........................................................     22

         3.12     Payments to or Reports by Affiliates............................................     22

         3.13     Payment of Additional Royalties.................................................     22

         3.14     Payments by Wire Transfer.......................................................     22

ARTICLE IV            DEVELOPMENT.................................................................     22

         4.1      Development Responsibility......................................................     22

         4.2      Development Plan................................................................     22

         4.3      Development Efforts.............................................................     23

         4.4      Drug Approval Applications......................................................     23

         4.5      Development Expenses............................................................     24

         4.6      Replacement Collaboration Compounds; Additional Collaboration Compounds.........     24

ARTICLE V             LICENSES....................................................................     25

         5.1      Patent Licenses to Conduct Development..........................................     25

         5.2      Patent Licenses to Conduct Commercialization Activities.........................     25

         5.3      Know-how Licenses...............................................................     25

         5.4      Distribution Through Third Party Distributors...................................     26

         5.5      Sublicensing....................................................................     26

         5.6      Third Party Technology..........................................................     26

         5.7      No Implied Licenses; Retained Rights............................................     26


                                      -iv-



                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         5.8      Independent Research............................................................     26

ARTICLE VI            COMMERCIALIZATION...........................................................     26

         6.1      Ortho as Marketing Party........................................................     27

         6.2      GTx's Option to Co-Promote in the United States.................................     27

         6.3      GTx to Notify Ortho of its Election to Co-Promote; Changes in the GTx Audience..     27

         6.4      Marketing and Sales Committee...................................................     28

         6.5      Marketing and Sales Plan........................................................     28

         6.6      Requirements for GTx Co-Promotion...............................................     29

         6.7      Co-Promotion Sales Forces.......................................................     29

         6.8      Sales Force Training............................................................     30

         6.9      GTx Sales Force.................................................................     31

         6.10     Detail Reports..................................................................     31

         6.11     Co-Promotion Audit of Performance...............................................     31

         6.12     Failure to Perform..............................................................     31

         6.13     Medical Inquiries...............................................................     32

         6.14     Governmental Contact............................................................     32

         6.15     Regulatory Disputes/Lawsuits....................................................     32

         6.16     Sales...........................................................................     32

         6.17     Orders..........................................................................     32

         6.18     Co-Promotion Limitation of Scope................................................     32

         6.19     Commercialization Efforts.......................................................     33

         6.20     Commercialization in Royalty Bearing Territory..................................     33

         6.21     Pricing, Pricing Approvals and Product Distribution.............................     33

         6.22     Product Recalls.................................................................     33

         6.23     Advertising and Promotion.......................................................     33

         6.24     GTx Right to Opt Out of Co-Promotion............................................     33

         6.25     Additional Support by GTx.......................................................     33

article VII           CO-PROMOTION PAYMENT........................................................     34

         7.1      Additional Royalty..............................................................     34


                                      -v-



                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         7.2      Term............................................................................     34

ARTICLE VIII          MANUFACTURE AND SUPPLY......................................................     35

         8.1      Manufacture and Supply During Development.......................................     35

         8.2      Manufacture and Supply During Commercialization.................................     35

         8.3      Clinical Supplies...............................................................     35

         8.4      Quality Assurance...............................................................     35

         8.5      Technology Transfer in Event of Termination by Ortho............................     36

ARTICLE IX            CONFIDENTIALITY.............................................................     36

         9.1      Confidentiality Exceptions......................................................     36

         9.2      Authorized Disclosure...........................................................     37

         9.3      Survival........................................................................     38

         9.4      Termination of Prior Agreement..................................................     38

         9.5      Publications....................................................................     38

         9.6      Public Disclosures..............................................................     38

ARTICLE X             OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS........................     39

         10.1     Ownership.......................................................................     39

         10.2     Invention Disclosures...........................................................     39

         10.3     Disclosure of Provisional and Non-Provisional Patent Applications...............     39

         10.4     Patent Filings..................................................................     40

         10.5     Third Party Patent Rights.......................................................     41

         10.6     Enforcement Rights..............................................................     41

         10.7     Defense and Settlement of Third Party Claims....................................     42

         10.8     Allocation of Patent Expenses...................................................     43

         10.9     Assignment of Joint Patents.....................................................     43

         10.10    Trademarks and Trademark Expenses...............................................     43

ARTICLE XI            REPRESENTATIONS AND WARRANTIES..............................................     43

         11.1     Representations and Warranties..................................................     43

         11.2     Performance by Affiliates.......................................................     44

ARTICLE XII           INFORMATION AND REPORTS.....................................................     44


                                      -vi-



                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         12.1     Information and Reports During Development and Commercialization................     44

         12.2     Complaints......................................................................     45

         12.3     Adverse Event Reporting.........................................................     45

         12.4     Records of Revenues and Expenses................................................     45

ARTICLE XIII          TERM AND TERMINATION........................................................     46

         13.1     Term............................................................................     46

         13.2     Termination for Material Breach.................................................     47

         13.3     Termination by Ortho............................................................     49

         13.4     Effect of Termination by GTx Under Section 13.2 or by Ortho Pursuant to
                  Section 13.3....................................................................     49

         13.5     Surviving Rights................................................................     50

         13.6     Change of Control...............................................................     50

ARTICLE XIV           INDEMNIFICATION.............................................................     54

         14.1     Ortho and GTx...................................................................     54

         14.2     Ortho...........................................................................     55

         14.3     Procedure.......................................................................     55

         14.4     Insurance.......................................................................     55

ARTICLE XV            DISPUTE RESOLUTION..........................................................     56

         15.1     Disputes........................................................................     56

         15.2     Disputes Referred First to Executive Officers...................................     56

         15.3     Resolution of Dispute by Alternate Means........................................     56

         15.4     Alternative Dispute Resolution..................................................     56

         15.5     Arbitration Procedures..........................................................     57

         15.6     Arbitrators.....................................................................     57

         15.7     Interim Review..................................................................     58

         15.8     Location........................................................................     58

         15.9     Discovery Proceedings...........................................................     58

         15.10    Hearings and Proceedings........................................................     59

         15.11    Award...........................................................................     60


                                     -vii-



                                TABLE OF CONTENTS
                                   (CONTINUED)



                                                                                                     PAGE
                                                                                                     ----
                                                                                                  
         15.12    Legal Fees......................................................................     60

         15.13    Confidentiality.................................................................     60

         15.14    Survivability...................................................................     60

         15.15    Jurisdiction....................................................................     60

ARTICLE XVI           MISCELLANEOUS...............................................................     61

         16.1     Assignment......................................................................     61

         16.2     Retained Rights.................................................................     61

         16.3     Consents Not Unreasonably Withheld or Delayed...................................     61

         16.4     Force Majeure...................................................................     61

         16.5     Further Actions.................................................................     62

         16.6     No Trademark Rights.............................................................     62

         16.7     Notices.........................................................................     62

         16.8     Waiver..........................................................................     62

         16.9     Severability....................................................................     63

         16.10    Ambiguities.....................................................................     63

         16.11    Governing Law...................................................................     63

         16.12    Headings........................................................................     63

         16.13    Counterparts....................................................................     63

         16.14    Entire Agreement; Amendments....................................................     63

         16.15    Independent Contractors.........................................................     64

         16.16    Currency Exchange...............................................................     64


[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE
COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED.

                                     -viii-

EXHIBIT 31.1

                      Chief Executive Officer Certification

I,  Mitchell S. Steiner, certify that:

         1. I have reviewed this quarterly report on Form 10-Q of GTx, Inc.;

         2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

         3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

         4. The registrant's other certifying officer(s)and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

                  (a) designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being
prepared;

                  (b) designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding reliability of
financial reporting and the preparation of financial statement for external
purposes in accordance with generally accepted accounting principles;

                  (c) evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation;

                  (d) disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting;
and

         5. The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent functions):

                  (a) all significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record,
summarize and report financial information; and

                  (b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's
internal control over financial reporting.

Dated: May 7, 2004                        /s/ Mitchell S. Steiner
                                          --------------------------------------
                                          Mitchell S. Steiner
                                          Chief Executive Officer

EXHIBIT 31.2

                      Chief Financial Officer Certification

I, Mark E. Mosteller, certify that:

         1. I have reviewed this quarterly report on Form 10-K of GTx, Inc.;

         2. Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;

         3. Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as
of, and for, the periods presented in this report;

         4. The registrant's other certifying officer(s) and I are responsible
for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

                  (a) designed such disclosure controls and procedures, or
caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within
those entities, particularly during the period in which this report is being
prepared;

                  (b) designed such internal control over financial reporting,
or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding reliability of
financial reporting and the preparation of financial statement for external
purposes in accordance with generally accepted accounting principles;

                  (c) evaluated the effectiveness of the registrant's disclosure
controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the
period covered by this report based on such evaluation;

                  (d) disclosed in this report any change in the registrant's
internal control over financial reporting that occurred during the registrant's
most recent fiscal quarter (the registrant's fourth fiscal quarter in the case
of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant's internal control over financial reporting;
and

         5. The registrant's other certifying officer(s) and I have disclosed,
based on our most recent evaluation of internal control over financial
reporting, to the registrant's auditors and the audit committee of registrant's
board of directors (or persons performing the equivalent functions):

                  (a) all significant deficiencies and material weaknesses in
the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to record,
summarize and report financial information; and

                  (b) any fraud, whether or not material, that involves
management or other employees who have a significant role in the registrant's
internal control over financial reporting.

 Dated: May 7, 2004                    /s/ Mark E. Mosteller
                                       -----------------------------------------
                                       Mark E. Mosteller
                                       Chief Financial Officer

EXHIBIT 32.1

                            CERTIFICATION PURSUANT TO
                            18 U. S. C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GTx, Inc. (the "Company") on Form
10-Q for the three months ending March 31, 2004, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Mitchell S.
Steiner, Chief Executive Officer of the Company certify, pursuant to 18 U.S.C..
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that:

         1.  The Report fully complies with the requirements of Section 13(a) or
             15(d) of the Securities Exchange Act of 1934; and

         2.  The information contained in the Report fairly presents, in all
             material respects, the financial condition and results of
             operations of the Company.

/s/ Mitchell S. Steiner
- -------------------------------------------
Mitchell S. Steiner
Chief Executive Officer

May 7, 2004

EXHIBIT 32.2

                            CERTIFICATION PURSUANT TO
                            18 U. S. C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of GTx, Inc. (the "Company") on Form
10-Q for the three months ending March 31, 2004, as filed with the Securities
and Exchange Commission on the date hereof (the "Report"), I, Mark E. Mosteller,
Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. ss. 1350,
as adopted pursuant to ss.906 of the Sarbanes-Oxley Act of 2002, that:

         1. The Report fully complies with the requirements of Section 13(a) or
            15(d) of the Securities Exchange Act of 1934; and

         2. The information contained in the Report fairly presents, in all
            material respects, the financial condition and results of
            operations of the Company.

/s/ Mark E. Mosteller
- -------------------------------------------
Mark E. Mosteller
Chief Financial Officer

May 7, 2004